Not all abdominal pain is gastrointestinal

Article Type
Changed
Display Headline
Not all abdominal pain is gastrointestinal

A 31-year-old woman presents to the office with a chief complaint of right mid-abdominal pain that began 1 day ago. She says she did not seek medical attention earlier because she had to be at work that morning and she thought the pain would resolve on its own.

She reports no fever, headache, anorexia, nausea, vomiting, malaise, loss of weight, melena, or changes in bowel habits. She describes the pain as sharp, localized to the right side, and radiating to the vulva upon sitting up. She denies any association of pain with current dietary habits or bowel function. She has no recollection of precipitating or alleviating factors, including the use of analgesics to reduce the pain.

On further discussion, she mentions that 1 year ago she began experiencing chronic abdominal pain, which she says is sometimes exacerbated by coughing, by standing for extended periods of time, and during menses, and is alleviated upon lying down.

She has regular menstrual periods, and her last one ended 7 days ago.

Her surgical history includes two uncomplicated cesarean deliveries. She does not use tobacco, alcohol, or illicit substances. She is not aware of any allergies to drugs or foods.

She appears to be in no acute distress and has been sitting quietly thus far. She seems to have positioned her hand on her abdomen over the corresponding area of pain.

On physical examination, vital signs are within normal limits, and she is alert and oriented to person, place, and time. Her sclerae are anicteric, and the pupils are equal, round, and reactive to light.

Her complete blood cell count, metabolic panel, and initial imaging tests are normal

Cardiovascular and pulmonary examinations are also within normal limits. Examination of the abdomen elicits tenderness and guarding along the lateral border of the rectus abdominis muscle on the right side at the level of umbilicus, with no rebound tenderness or rigidity. The liver and spleen are not enlarged, and no abdominal mass is detected. No skin rash, joint swelling, or peripheral edema is noted. A neurologic examination is normal.

1. With the information provided, which of the following is least likely to be causing her symptoms?

  • Chronic mesenteric ischemia
  • Peptic ulcer
  • Acute cholecystitis
  • Slipping rib syndrome

CHRONIC MESENTERIC ISCHEMIA

Chronic mesenteric ischemia is the least likely diagnosis because the patient lacks risk factors for atherosclerosis and because she does not have postprandial pain, which is pathognomonic for chronic mesenteric ischemia. It is thought to be caused by a decrease in blood flow through the splanchnic vessels.1 Symptoms tend to arise after eating because of a postprandial increase in metabolic demands.1 These patients also often have atherosclerotic risk factors such as hypertension, hyperlipidemia, and smoking causing coronary artery disease, or a history of stroke.

The primary symptom is abdominal pain, most often described as achy, crampy, or spastic episodes of pain, usually occurring within 2 hours of eating.2 Weight loss is common, as patients can develop a fear of eating. Postprandial pain may also be associated with nausea, vomiting, and bloating.

Findings on clinical examination are usually less severe than the actual symptoms. Visceral duplex or multidetector computed tomography (CT) is an excellent tool to detect blood flow in potential stenotic vessels.2

PEPTIC ULCER DISEASE

Peptic ulcer disease is not a likely diagnosis in this patient because she has no history of taking nonsteroidal anti-inflammatory drugs (NSAIDs).

A study of US patients between 1997 and 2007 reported an annual incidence of peptic ulcer disease of 0.05% to 0.19% depending on the method of diagnosis.3 Peptic ulcer is thought to result from increased gastric acid secretion with a resultant inflammatory response, leading to erosion and ulceration.

The most common possible catalysts include Helicobacter pylori infection, NSAIDs, smoking, alcohol use, and hypersecretory states such as Zollinger-Ellison syndrome.4–6 Complications include internal bleeding, perforation causing peritonitis, and penetration to adjacent organs.

Pathophysiology

Peptic ulcer is the result of an increase in the normal level of gastric acid and a decrease in the protective ability of the gastric mucosa.7 Cytoprotection may be lost through a decrease in the products of arachidonic acid metabolism (eg, prostaglandins, which have a protective effect) or an increase in leukotriene B4 (LTB4), which has a damaging effect. Prostaglandins are thought not only to protect the normal gastric mucosa, but also to provide an antisecretory effect.

On the other hand, leukotrienes—specifically LTB4 and LTC4—are proinflammatory agents and can damage the gastric mucosa. NSAIDs enhance the production of leuko­trienes through the 5-lipoxygenase pathway. The ability of LTB4 to cause degranulation and release of lysosomal enzymes may play a vital role in the inflammatory response to NSAIDs.8–10 LTC4 may promote gastric mucosal damage through a reduction of tissue perfusion resulting from the promotion of vascular stasis.8,11,12

Symptoms help differentiate ulcer type

The classic symptom is burning epigastric pain after meals. Pain that occurs immediately after meals is a classic symptom of gastric ulcer. Pain that occurs 2 to 3 hours after meals and that is relieved by food or antacids is a strong indicator of duodenal ulcer.13 Other symptoms include dyspepsia, bloating, distention, heartburn, and chest discomfort.13

Accurate diagnosis is vital in selecting the proper treatment. Diagnostic tests may include H pylori testing, upper-gastrointestinal endoscopy, and radiography with barium swallow.

CHOLECYSTITIS

In cholecystitis, the primary complaint is pain, usually in the right upper quadrant of the abdomen. Patients describe sudden, sharp, and intense pain that radiates to the back or shoulder. Patients may report pain after heavy meals, and some report nausea and vomiting. Cholecystitis is in the differential diagnosis of this patient because of the anatomic location of her pain.

The diagnosis is confirmed by imaging. Abdominal ultrasonography, technetium-99m hepatic iminodiacetic acid scanning, and CT are the most commonly used studies.14

Cholecystitis can be acute or chronic. Acute cholecystitis is categorized as calculous or acalculous. Calculous cholecystitis is multifactorial, but the primary cause is blockage of the cystic duct by gallstones.15 Other factors include irritants such as lysolecithin (released during bile stasis), which can trigger gallbladder inflammation,15–17 and infection.18

When the cystic duct is blocked, bile builds up inside the gallbladder, causing irritation and inflammation of the walls of the gallbladder.14

Acalculous cholecystitis, which resembles calculous cholecystitis but without the gallstones,19 accounts for 2% to 15% of all cases of acute cholecystitis.19,20 It has been observed in hospitalized critically ill patients, but it can also present in an outpatient setting, most often in elderly men with vascular disease.21 Causes include infection, trauma, and tumor obstruction, resulting in endothelial injury, gallbladder stasis, ischemia, and eventually necrosis.14,20,22,23

SLIPPING RIB SYNDROME

Slipping rib syndrome, also known as Tietze syndrome, is believed to be caused by hypermobile costal cartilage. The affected rib slips behind the rib above on contraction of the abdominal wall. This displacement increases the probability of costal nerve impingement and tissue inflammation producing unilateral, sharp, subcostal and upper-abdominal pain.

In this patient, slipping rib syndrome is a possible diagnosis because of the location of the pain and because the pain described by the patient is highly suggestive of neuropathic pain.

Slipping rib syndrome is diagnosed clinically by a “hooking” maneuver: the clinician hooks his or her fingers at the patient’s subcostal area, reproducing the pain by movement of the ribs anteriorly.24 When this test is performed in our patient the result is negative, ruling out slipping rib syndrome.

THE WORKUP CONTINUES

A complete blood cell count and comprehensive metabolic panel are within normal limits. Abdominal duplex ultrasonography reveals no celiac or mesenteric occlusions, thus ruling out chronic mesenteric ischemia.

Noncontrast CT shows no renal or ureteric stones and no evidence of bleeding in the urinary tract. CT with contrast shows no bowel distention, no evidence of hernia, and a normal appendix and ovaries.

2. After exclusion of the previous choices, which of the following is the most likely cause of her symptoms?

  • Anterior cutaneous nerve entrapment syndrome (ACNES)
  • Ovarian cyst
  • Renal stones
  • Appendicitis
  • Ventral hernia
  • Median arcuate ligament syndrome
 

 

ANTERIOR CUTANEOUS NERVE ENTRAPMENT SYNDROME

ACNES is the most likely diagnosis. A study published in 2013 indicated that many cases of functional abdominal pain may actually be undiagnosed cases of chronic abdominal wall pain such as ACNES.25 The condition, first described in 1972,26 is thought to be caused by thoracic cutaneous intercostal nerve entrapment between the abdominal muscles, causing pain at the point of entrapment.

The patient may present with pain that is either acute or chronic. Acute pain is localized more on the right side close to an old scar, or at the outer edge of the rectus abdominis muscle. The pain may vary from dull to burning to sharp; it can radiate horizontally in the upper half of the abdomen or obliquely in the lower half of the abdomen with movements such as twisting and sitting up.27

Despite the acute pain, patients are able to carry on daily functions. The pain may be alleviated by lying down.

The pain may be misdiagnosed as gynecologic or renal. In younger men, the pain may raise concern about hernia, and in older patients, cancer.27 Patients may complain of chronic intermittent pain, usually unilateral, and to a lesser extent bilateral.27

The anatomic location of the pain usually reflects the intercostal nerve involved. The pain is not related to eating or to bowel movements.25 Some patients report exacerbation upon coughing or standing, during menses, and with use of oral contraceptives.28,29 When inquiring about surgical history, it is common to find that the patient has had multiple abdominal surgical procedures.

On examination, the patient has nondistressing pain, with a hand often placed over the painful area.27 On firm palpation, a tender spot of less than 2 cm can be detected.

The diagnosis can be confirmed with a positive Carnett test. The patient lies supine on the examination table with the arms crossed over the chest, then elevates the head or the feet to tense the abdominal muscles.26,27 If doing so reproduces the pain (ie, a positive test), this increases the suspicion of ACNES; if the pain decreases or is not reproducible, an intra-abdominal cause is more likely.

A positive Carnett test helps rule out visceral involvement

If the pain is difficult to localize, the “pinch test” can be done by using the thumb and index finger to pinch and lift the skin of the abdomen, including the subcutaneous layer of fat, first on one side and then on the other. This helps determine the side with greater pain.27

OVARIAN CYSTS

Ovarian cysts are fluid-filled sacs on the surface of or within the ovary. They are often benign and require no intervention. However, 5% to 10% of US women with a suspicious ovarian mass undergo a surgical procedure, and 13% to 21% of these are found to have a malignancy.30,31

Ovarian cysts are usually painless unless complicated by rupture or bleeding. Patients who present with pain describe it as dull and aching and in the abdomen or pelvis. In rare cases, ovarian cysts can be large enough to cause pain from torsion. Other symptoms may include delayed menses and bleeding outside of the menstrual period.32–34

Ovarian cysts are thought to be caused by hormonal changes during the menstrual cycle. They can be detected during pelvic examination or during pelvic ultrasonography. Cysts that are primarily fluid-filled are generally benign and require no intervention. On the other hand, cysts composed of solid material require intervention.

Treatment depends on several factors, including size and type of cyst, the patient’s age, and whether torsion is present. Treatment can range from observation to medical or surgical management. Laparoscopic surgery is commonly used when surgical treatment is warranted.

RENAL STONES

From 10% to 15% of US adults develop a kidney stone at some time during their life.35 There is no single cause, but one factor that promotes stone formation is a greater amount of crystal-forming substances in the urine, such as calcium, oxalate, and uric acid.36 Most renal stones are calcium oxalate, uric acid, struvite, or cysteine.

Symptoms arise when the stone moves within the urinary tract. Patients present to the emergency room in severe distress, usually with flank pain that radiates to the lower abdomen or groin. The pain is episodic, fluctuates in intensity, and may present with dysuria, frequency, or urgency. It is also associated with nausea and vomiting.37

Renal stones are diagnosed through a series of laboratory and imaging studies. Imaging studies include plain radiography (which can miss small stones), renal sonography, and computed tomography without contrast.

APPENDICITIS

In the United States, the lifetime risk of developing appendicitis is 8.6% in men and 6.7% in women.38 Appendicitis is one of the most common reasons for emergency surgery.

Appendicitis is thought to result from obstruction by fecal matter blocking the opening of the appendix or from a viral infection (eg, with an adenovirus).39,40 The resulting bacterial growth can cause the appendix to become inflamed and purulent.

Patients typically present with umbilical or epigastric pain radiating to the right lower quadrant of the abdomen. Over time, the pain becomes sharper. Certain movements can exacerbate the pain, and lying down may alleviate it. Other symptoms are nausea, vomiting, loss of appetite, and low-grade fever.

If the pain is difficult to localize, the ‘pinch test’ can help determine the more painful side

Findings on the abdominal examination that help to confirm the diagnosis include rigidity and tenderness, classically localized to a point two-thirds of the way from the umbilicus to the anterior superior iliac spine. Rebound tenderness is usually present. Up to 25% of cases in some series presented atypically, with variable location and findings on physical examination (eg, bowel irregularities, indigestion, flatulence, generalized malaise). In addition to the physical examination, laboratory testing and imaging (ultrasonography, CT) may aid in confirming the diagnosis of appendicitis or any other cause of the pain.38

VENTRAL HERNIA

Ventral hernia is a bulging of abdominal organs or other tissues through a defect of the musculature of the abdominal wall. Ventral hernia is categorized by its location as epigastric, abdominal, or incisional. An open abdominal procedure is the cause in nearly 10% of cases41; the herniation occurs with weakening of the surgical scar.

Ventral hernia is usually detected on physical examination, and patients may present after noting a bulge in the abdominal wall. Symptoms vary. Some patients have no symptoms, while others have mild abdominal discomfort or severe abdominal pain as well as nausea and vomiting. Imaging with CT, ultrasonography, or magnetic resonance imaging helps confirm the diagnosis. Complications of ventral hernia include incarceration and bowel strangulation.

MEDIAN ARCUATE LIGAMENT SYNDROME

Median arcuate ligament syndrome is a challenging diagnosis and a very rare cause of abdominal pain. It is thought to be caused by celiac artery compression by fibroligamentous bands. Pain fluctuates with respiration and is greater during expiration.

Patients may present with recurrent episodes of crampy postprandial pain that cause them to avoid eating, resulting in weight loss. The pain may be associated with nausea, vomiting, and bloating.

The diagnosis is confirmed by duplex ultrasonography, angiography, or magnetic resonance angiography. Treatment is surgical division of the fibroligamentous band and crus, and this is often done laparascopically. In patients with severe persistent celiac artery stenosis, angioplasty and stenting may be considered.2

CASE CONTINUED

Before the physical examination, our patient identifies the location of her pain. A Carnett test is performed, as for ACNES: the patient is placed in the supine position and is instructed to cross both arms over her chest. In an effort to promote muscle tension, she is asked to elevate her head off the examination table, as if performing a mini sit-up, and as she does this, pressure is applied to the identified tender area. The pain is easily reproduced, further confirming involvement of the abdominal wall rather than the viscera. After this, electromyography shows abnormal findings. The patient is then  referred to the pain management clinic for a diagnostic nerve block.

3. Which of the following is the first-line treatment of ACNES?

  • Local injection of anesthetic
  • Surgical neurectomy

LOCAL INJECTION OF ANESTHETIC

Local injection of anesthetic is the first-line treatment of ACNES.

Figure 1. After the needle is advanced just beyond the fascia and into the rectus abdominis muscle (arrow) under ultrasonographic guidance, 5 mL of 0.25% bupivacaine and 40 mg of triamcinolone are injected into the muscle, providing relief of the pain. An injection of 2% lidocaine may be done as a test block. Higher concentrations of anesthetic are to be avoided, as they may cause a motor block.

Since ACNES is underdiagnosed, the patient may be less likely to be familiar with it. He or she should receive a detailed explanation of the condition and its management; this will help achieve a successful outcome.

Local anesthetic injection is used for both diagnosis and treatment; 2% lidocaine (or an equivalent) or dehydrated (absolute) alcohol or both can eliminate the pain caused by ACNES. The injection is commonly done under ultrasonographic guidance (Figure 1).42

Complete pain relief may be achieved with a single injection, but some patients require up to five injections.

The adjuvant use of corticosteroids in ACNES to reduce inflammation is controversial.

If anesthetic injections bring only minimal pain relief or if the patient has nerve entrapment in a scar, then surgical neurectomy is an option.43 The procedure is performed under local anesthesia, as the patient’s response aids in identifying the specific nerve or nerves involved.

RETURNING TO THE PATIENT

After a long discussion with our patient about ACNES and the treatment options, she  agrees to undergo nerve block in the hope of relieving her pain. She receives a 0.5-mL injection of 2% lidocaine subcutaneously, and within minutes she reports relief of pain. She cannot believe that with a simple injection her pain was relieved. We advise her to return if her pain recurs or if new symptoms arise.

KEEP ACNES IN MIND

ACNES is one of the most commonly misdiagnosed conditions of patients presenting to the outpatient clinic with acute or chronic abdominal pain. This is because the focus is directed to intra-abdominal causes. But if ACNES is kept in consideration from the beginning of the patient encounter, extensive testing, time, and patient anxiety may be reduced significantly. A simple physical examination and the Carnett test aid in raising suspicion of ACNES. If ACNES is confirmed, ultrasonographically guided local anesthetic injection is both diagnostic and therapeutic.

References
  1. American Gastroenterological Association Medical Position Statement: Guidelines On Intestinal Ischemia. Gastroenterology 2000; 118:951–953.
  2. Bobadilla JL. Mesenteric ischemia. Surg Clin North Am 2013; 93:925–940.
  3. Sung JJ, Kuipers EJ, El-Serag HB. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther 2009; 29:938–946.
  4. Najm WI. Peptic ulcer disease. Prim Care 2011; 38:383–394.
  5. Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet 2009; 374:1449–1461.
  6. Chan FK, Leung WK. Peptic-ulcer disease. Lancet 2002; 360:933–941.
  7. Bright-Asare P, Habte T, Yirgou B, Benjamin J. Prostaglandins, H2-receptor antagonists and peptic ulcer disease. Drugs 1988; 35(suppl 3):1–9.
  8. Hudson N, Balsitis M, Everitt S, Hawkey CJ. Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993; 34:742–747.
  9. Ford-Hutchinson AW, Bray MA, Doig MV, Shipley ME, Smith MJ. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 1980; 286:264–265.
  10. Bokoch GM, Reed PW. Effect of various lipoxygenase metabolites of arachidonic acid on degranulation of polymorphonuclear leukocytes. J  Biol Chem 1981; 256:5317–5320.
  11. Whittle BJ, Oren-Wolman N, Guth PH. Gastric vasoconstrictor actions of leukotriene C4, PGF2 alpha, and thromboxane mimetic U-46619 on rat submucosal microcirculation in vivo. Am J Physiol 1985; 248:G580–G586.
  12. Pihan G, Rogers C, Szabo S. Vascular injury in acute gastric mucosal damage. Mediatory role of leukotrienes. Dig Dis Sci 1988; 33:625–632.
  13. Ramakrishnan K, Salinas RC. Peptic ulcer disease. Am Fam Physician 2007; 76:1005–1012.
  14. Parmet S, Lynm C, Glass RM. JAMA patient page. Acute cholecystitis. JAMA 2003; 289:124.
  15. Roslyn JJ, DenBesten L, Thompson JE Jr, Silverman BF. Roles of lithogenic bile and cystic duct occlusion in the pathogenesis of acute cholecystitis. Am J Surg 1980; 140:126–130.
  16. Kaminski DL. Arachidonic acid metabolites in hepatobiliary physiology and disease. Gastroenterology 1989; 97:781–792.
  17. Jivegård L, Thornell E, Svanvik J. Pathophysiology of acute obstructive cholecystitis: implications for non-operative management. Br J Surg 1987; 74:1084–1086.
  18. Csendes A, Burdiles P, Maluenda F, Diaz JC, Csendes P, Mitru N. Simultaneous bacteriologic assessment of bile from gallbladder and common bile duct in control subjects and patients with gallstones and common duct stones. Arch Surg 1996; 131:389–394.
  19. Barie PS, Fischer E. Acute acalculous cholecystitis. J Am Coll Surg 1995; 180:232–244.
  20. Shapiro MJ, Luchtefeld WB, Kurzweil S, Kaminski DL, Durham RM, Mazuski JE. Acute acalculous cholecystitis in the critically ill. Am Surg 1994; 60:335–339.
  21. Savoca PE, Longo WE, Zucker KA, McMillen MM, Modlin IM. The increasing prevalence of acalculous cholecystitis in outpatients. Results of a 7-year study. Ann Surg 1990; 211:433–437.
  22. Gofrit O, Eid A, Pikarsky A, Lebensart PD, Pizov G, Rivkind A. Cholesterol embolisation causing chronic acalculous cholecystitis. Eur J Surg 1996; 162:243–245.
  23. McChesney JA, Northup PG, Bickston SJ. Acute acalculous cholecystitis associated with systemic sepsis and visceral arterial hypoperfusion: a case series and review of pathophysiology. Dig Dis Sci 2003; 48:1960–1967.
  24. Aeschlimann A, Kahn MF. Tietze’s syndrome: a critical review. Clin Exp Rheumatol 1990; 8:407–412.
  25. van Assen T, de Jager-Kievit JW, Scheltinga MR, Roumen RM. Chronic abdominal wall pain misdiagnosed as functional abdominal pain. J Am Board Fam Med 2013; 26:738–744.
  26. Akhnikh S, de Korte N, de Winter P. Anterior cutaneous nerve entrapment syndrome (ACNES): the forgotten diagnosis. Eur J Pediatr 2014; 173:445–449.
  27. Applegate WV. Abdominal cutaneous nerve entrapment syndrome (ACNES): a commonly overlooked cause of abdominal pain. Perm J 2002; 6:20–27.
  28. Grover M. UNC Center for Functional GI & Motility Disorders. Chronic abdominal wall pain: a missed diagnosis. www.med.unc.edu/ibs/files/educational-gi-handouts/Chronic%20Abdominal%20Pain.pdf. Accessed September 9, 2015.
  29. Greenbaum D, Dawson F, Watson R. Chronic abdominal wall pain (CAWP): a common but frequently overlooked disorder. Poster presented at the World Congress of Gastroenterology, Sydney, Australia, August 26–31, 1990.
  30. National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up. Gynecol Oncol 1994; 55:S4–S14.
  31. Koonings PP, Campbell K, Mishell DR Jr, Grimes DA. Relative frequency of primary ovarian neoplasms: a 10-year review. Obstet Gynecol 1989; 74:921–926.
  32. Givens V, Mitchell GE, Harraway-Smith C, Reddy A, Maness DL. Diagnosis and management of adnexal masses. Am Fam Physician 2009; 80:815–820.
  33. Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer 2000; 89:2068–2075.
  34. Friedman GD, Skilling JS, Udaltsova NV, Smith LH. Early symptoms of ovarian cancer: a case-control study without recall bias. Fam Pract 2005; 22:548–553.
  35. Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int 2003; 63:1817–1823.
  36. Worcester EM, Coe FL. Clinical practice. Calcium kidney stones. N Engl J Med 2010; 363:954–963.
  37. Miller NL, Lingeman JE. Management of kidney stones. BMJ 2007; 334:468–472.
  38. Lewis SR, Mahony PJ, Simpson J. Appendicitis. BMJ 2011; 343:d5976.
  39. Lamps LW. Infectious causes of appendicitis. Infect Dis Clin North Am 2010; 24:995–1018.
  40. Reif RM. Viral appendicitis. Hum Pathol 1981; 12:193–196.
  41. Akkary E, Panait L, Roberts K, Duffy A, Bell R. Sutureless laparoscopic ventral hernia repair in obese patients. JSLS 2011; 15:154–159.
  42. Boelens OB, Scheltinga MR, Houterman S, Roumen RM. Randomized clinical trial of trigger point infiltration with lidocaine to diagnose anterior cutaneous nerve entrapment syndrome. Br J Surg 2013; 100:217–221.
  43. Boelens OB, Scheltinga MR, Houterman S, Roumen RM. Management of anterior cutaneous nerve entrapment syndrome in a cohort of 139 patients. Ann Surg 2011; 254:1054–1058.
Article PDF
Author and Disclosure Information

Mena Boules, MD
Digestive Disease Institute, Cleveland Clinic

Madonna Michael, MD
Department of Internal Medicine, Cleveland Clinic

Julietta Chang, MD
Digestive Disease Institute, Cleveland Clinic

Bruce Vrooman, MD
Department of Pain Management, Cleveland Clinic

Matthew Kroh, MD
Digestive Disease Institute, Cleveland Clinic

Maged Rizk, MD
Digestive Disease Institute, Cleveland Clinic

Address: Maged Rizk, MD, Digestive Disease Institute, A30, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: rizkm@ccf.org

Issue
Cleveland Clinic Journal of Medicine - 83(1)
Publications
Topics
Page Number
29-35
Legacy Keywords
abdominal pain, mesenteric ischemia, peptic ulcer, cholecystitis, slipping rib syndrome, nerve entrapment, anterior cutaneous nerve entrapment syndrome, ACNES, Mena Boules, Madonna Michael, Julietta Chang, Bruce Vrooman, Matthew Kroh, Maged Rizk
Sections
Author and Disclosure Information

Mena Boules, MD
Digestive Disease Institute, Cleveland Clinic

Madonna Michael, MD
Department of Internal Medicine, Cleveland Clinic

Julietta Chang, MD
Digestive Disease Institute, Cleveland Clinic

Bruce Vrooman, MD
Department of Pain Management, Cleveland Clinic

Matthew Kroh, MD
Digestive Disease Institute, Cleveland Clinic

Maged Rizk, MD
Digestive Disease Institute, Cleveland Clinic

Address: Maged Rizk, MD, Digestive Disease Institute, A30, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: rizkm@ccf.org

Author and Disclosure Information

Mena Boules, MD
Digestive Disease Institute, Cleveland Clinic

Madonna Michael, MD
Department of Internal Medicine, Cleveland Clinic

Julietta Chang, MD
Digestive Disease Institute, Cleveland Clinic

Bruce Vrooman, MD
Department of Pain Management, Cleveland Clinic

Matthew Kroh, MD
Digestive Disease Institute, Cleveland Clinic

Maged Rizk, MD
Digestive Disease Institute, Cleveland Clinic

Address: Maged Rizk, MD, Digestive Disease Institute, A30, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: rizkm@ccf.org

Article PDF
Article PDF
Related Articles

A 31-year-old woman presents to the office with a chief complaint of right mid-abdominal pain that began 1 day ago. She says she did not seek medical attention earlier because she had to be at work that morning and she thought the pain would resolve on its own.

She reports no fever, headache, anorexia, nausea, vomiting, malaise, loss of weight, melena, or changes in bowel habits. She describes the pain as sharp, localized to the right side, and radiating to the vulva upon sitting up. She denies any association of pain with current dietary habits or bowel function. She has no recollection of precipitating or alleviating factors, including the use of analgesics to reduce the pain.

On further discussion, she mentions that 1 year ago she began experiencing chronic abdominal pain, which she says is sometimes exacerbated by coughing, by standing for extended periods of time, and during menses, and is alleviated upon lying down.

She has regular menstrual periods, and her last one ended 7 days ago.

Her surgical history includes two uncomplicated cesarean deliveries. She does not use tobacco, alcohol, or illicit substances. She is not aware of any allergies to drugs or foods.

She appears to be in no acute distress and has been sitting quietly thus far. She seems to have positioned her hand on her abdomen over the corresponding area of pain.

On physical examination, vital signs are within normal limits, and she is alert and oriented to person, place, and time. Her sclerae are anicteric, and the pupils are equal, round, and reactive to light.

Her complete blood cell count, metabolic panel, and initial imaging tests are normal

Cardiovascular and pulmonary examinations are also within normal limits. Examination of the abdomen elicits tenderness and guarding along the lateral border of the rectus abdominis muscle on the right side at the level of umbilicus, with no rebound tenderness or rigidity. The liver and spleen are not enlarged, and no abdominal mass is detected. No skin rash, joint swelling, or peripheral edema is noted. A neurologic examination is normal.

1. With the information provided, which of the following is least likely to be causing her symptoms?

  • Chronic mesenteric ischemia
  • Peptic ulcer
  • Acute cholecystitis
  • Slipping rib syndrome

CHRONIC MESENTERIC ISCHEMIA

Chronic mesenteric ischemia is the least likely diagnosis because the patient lacks risk factors for atherosclerosis and because she does not have postprandial pain, which is pathognomonic for chronic mesenteric ischemia. It is thought to be caused by a decrease in blood flow through the splanchnic vessels.1 Symptoms tend to arise after eating because of a postprandial increase in metabolic demands.1 These patients also often have atherosclerotic risk factors such as hypertension, hyperlipidemia, and smoking causing coronary artery disease, or a history of stroke.

The primary symptom is abdominal pain, most often described as achy, crampy, or spastic episodes of pain, usually occurring within 2 hours of eating.2 Weight loss is common, as patients can develop a fear of eating. Postprandial pain may also be associated with nausea, vomiting, and bloating.

Findings on clinical examination are usually less severe than the actual symptoms. Visceral duplex or multidetector computed tomography (CT) is an excellent tool to detect blood flow in potential stenotic vessels.2

PEPTIC ULCER DISEASE

Peptic ulcer disease is not a likely diagnosis in this patient because she has no history of taking nonsteroidal anti-inflammatory drugs (NSAIDs).

A study of US patients between 1997 and 2007 reported an annual incidence of peptic ulcer disease of 0.05% to 0.19% depending on the method of diagnosis.3 Peptic ulcer is thought to result from increased gastric acid secretion with a resultant inflammatory response, leading to erosion and ulceration.

The most common possible catalysts include Helicobacter pylori infection, NSAIDs, smoking, alcohol use, and hypersecretory states such as Zollinger-Ellison syndrome.4–6 Complications include internal bleeding, perforation causing peritonitis, and penetration to adjacent organs.

Pathophysiology

Peptic ulcer is the result of an increase in the normal level of gastric acid and a decrease in the protective ability of the gastric mucosa.7 Cytoprotection may be lost through a decrease in the products of arachidonic acid metabolism (eg, prostaglandins, which have a protective effect) or an increase in leukotriene B4 (LTB4), which has a damaging effect. Prostaglandins are thought not only to protect the normal gastric mucosa, but also to provide an antisecretory effect.

On the other hand, leukotrienes—specifically LTB4 and LTC4—are proinflammatory agents and can damage the gastric mucosa. NSAIDs enhance the production of leuko­trienes through the 5-lipoxygenase pathway. The ability of LTB4 to cause degranulation and release of lysosomal enzymes may play a vital role in the inflammatory response to NSAIDs.8–10 LTC4 may promote gastric mucosal damage through a reduction of tissue perfusion resulting from the promotion of vascular stasis.8,11,12

Symptoms help differentiate ulcer type

The classic symptom is burning epigastric pain after meals. Pain that occurs immediately after meals is a classic symptom of gastric ulcer. Pain that occurs 2 to 3 hours after meals and that is relieved by food or antacids is a strong indicator of duodenal ulcer.13 Other symptoms include dyspepsia, bloating, distention, heartburn, and chest discomfort.13

Accurate diagnosis is vital in selecting the proper treatment. Diagnostic tests may include H pylori testing, upper-gastrointestinal endoscopy, and radiography with barium swallow.

CHOLECYSTITIS

In cholecystitis, the primary complaint is pain, usually in the right upper quadrant of the abdomen. Patients describe sudden, sharp, and intense pain that radiates to the back or shoulder. Patients may report pain after heavy meals, and some report nausea and vomiting. Cholecystitis is in the differential diagnosis of this patient because of the anatomic location of her pain.

The diagnosis is confirmed by imaging. Abdominal ultrasonography, technetium-99m hepatic iminodiacetic acid scanning, and CT are the most commonly used studies.14

Cholecystitis can be acute or chronic. Acute cholecystitis is categorized as calculous or acalculous. Calculous cholecystitis is multifactorial, but the primary cause is blockage of the cystic duct by gallstones.15 Other factors include irritants such as lysolecithin (released during bile stasis), which can trigger gallbladder inflammation,15–17 and infection.18

When the cystic duct is blocked, bile builds up inside the gallbladder, causing irritation and inflammation of the walls of the gallbladder.14

Acalculous cholecystitis, which resembles calculous cholecystitis but without the gallstones,19 accounts for 2% to 15% of all cases of acute cholecystitis.19,20 It has been observed in hospitalized critically ill patients, but it can also present in an outpatient setting, most often in elderly men with vascular disease.21 Causes include infection, trauma, and tumor obstruction, resulting in endothelial injury, gallbladder stasis, ischemia, and eventually necrosis.14,20,22,23

SLIPPING RIB SYNDROME

Slipping rib syndrome, also known as Tietze syndrome, is believed to be caused by hypermobile costal cartilage. The affected rib slips behind the rib above on contraction of the abdominal wall. This displacement increases the probability of costal nerve impingement and tissue inflammation producing unilateral, sharp, subcostal and upper-abdominal pain.

In this patient, slipping rib syndrome is a possible diagnosis because of the location of the pain and because the pain described by the patient is highly suggestive of neuropathic pain.

Slipping rib syndrome is diagnosed clinically by a “hooking” maneuver: the clinician hooks his or her fingers at the patient’s subcostal area, reproducing the pain by movement of the ribs anteriorly.24 When this test is performed in our patient the result is negative, ruling out slipping rib syndrome.

THE WORKUP CONTINUES

A complete blood cell count and comprehensive metabolic panel are within normal limits. Abdominal duplex ultrasonography reveals no celiac or mesenteric occlusions, thus ruling out chronic mesenteric ischemia.

Noncontrast CT shows no renal or ureteric stones and no evidence of bleeding in the urinary tract. CT with contrast shows no bowel distention, no evidence of hernia, and a normal appendix and ovaries.

2. After exclusion of the previous choices, which of the following is the most likely cause of her symptoms?

  • Anterior cutaneous nerve entrapment syndrome (ACNES)
  • Ovarian cyst
  • Renal stones
  • Appendicitis
  • Ventral hernia
  • Median arcuate ligament syndrome
 

 

ANTERIOR CUTANEOUS NERVE ENTRAPMENT SYNDROME

ACNES is the most likely diagnosis. A study published in 2013 indicated that many cases of functional abdominal pain may actually be undiagnosed cases of chronic abdominal wall pain such as ACNES.25 The condition, first described in 1972,26 is thought to be caused by thoracic cutaneous intercostal nerve entrapment between the abdominal muscles, causing pain at the point of entrapment.

The patient may present with pain that is either acute or chronic. Acute pain is localized more on the right side close to an old scar, or at the outer edge of the rectus abdominis muscle. The pain may vary from dull to burning to sharp; it can radiate horizontally in the upper half of the abdomen or obliquely in the lower half of the abdomen with movements such as twisting and sitting up.27

Despite the acute pain, patients are able to carry on daily functions. The pain may be alleviated by lying down.

The pain may be misdiagnosed as gynecologic or renal. In younger men, the pain may raise concern about hernia, and in older patients, cancer.27 Patients may complain of chronic intermittent pain, usually unilateral, and to a lesser extent bilateral.27

The anatomic location of the pain usually reflects the intercostal nerve involved. The pain is not related to eating or to bowel movements.25 Some patients report exacerbation upon coughing or standing, during menses, and with use of oral contraceptives.28,29 When inquiring about surgical history, it is common to find that the patient has had multiple abdominal surgical procedures.

On examination, the patient has nondistressing pain, with a hand often placed over the painful area.27 On firm palpation, a tender spot of less than 2 cm can be detected.

The diagnosis can be confirmed with a positive Carnett test. The patient lies supine on the examination table with the arms crossed over the chest, then elevates the head or the feet to tense the abdominal muscles.26,27 If doing so reproduces the pain (ie, a positive test), this increases the suspicion of ACNES; if the pain decreases or is not reproducible, an intra-abdominal cause is more likely.

A positive Carnett test helps rule out visceral involvement

If the pain is difficult to localize, the “pinch test” can be done by using the thumb and index finger to pinch and lift the skin of the abdomen, including the subcutaneous layer of fat, first on one side and then on the other. This helps determine the side with greater pain.27

OVARIAN CYSTS

Ovarian cysts are fluid-filled sacs on the surface of or within the ovary. They are often benign and require no intervention. However, 5% to 10% of US women with a suspicious ovarian mass undergo a surgical procedure, and 13% to 21% of these are found to have a malignancy.30,31

Ovarian cysts are usually painless unless complicated by rupture or bleeding. Patients who present with pain describe it as dull and aching and in the abdomen or pelvis. In rare cases, ovarian cysts can be large enough to cause pain from torsion. Other symptoms may include delayed menses and bleeding outside of the menstrual period.32–34

Ovarian cysts are thought to be caused by hormonal changes during the menstrual cycle. They can be detected during pelvic examination or during pelvic ultrasonography. Cysts that are primarily fluid-filled are generally benign and require no intervention. On the other hand, cysts composed of solid material require intervention.

Treatment depends on several factors, including size and type of cyst, the patient’s age, and whether torsion is present. Treatment can range from observation to medical or surgical management. Laparoscopic surgery is commonly used when surgical treatment is warranted.

RENAL STONES

From 10% to 15% of US adults develop a kidney stone at some time during their life.35 There is no single cause, but one factor that promotes stone formation is a greater amount of crystal-forming substances in the urine, such as calcium, oxalate, and uric acid.36 Most renal stones are calcium oxalate, uric acid, struvite, or cysteine.

Symptoms arise when the stone moves within the urinary tract. Patients present to the emergency room in severe distress, usually with flank pain that radiates to the lower abdomen or groin. The pain is episodic, fluctuates in intensity, and may present with dysuria, frequency, or urgency. It is also associated with nausea and vomiting.37

Renal stones are diagnosed through a series of laboratory and imaging studies. Imaging studies include plain radiography (which can miss small stones), renal sonography, and computed tomography without contrast.

APPENDICITIS

In the United States, the lifetime risk of developing appendicitis is 8.6% in men and 6.7% in women.38 Appendicitis is one of the most common reasons for emergency surgery.

Appendicitis is thought to result from obstruction by fecal matter blocking the opening of the appendix or from a viral infection (eg, with an adenovirus).39,40 The resulting bacterial growth can cause the appendix to become inflamed and purulent.

Patients typically present with umbilical or epigastric pain radiating to the right lower quadrant of the abdomen. Over time, the pain becomes sharper. Certain movements can exacerbate the pain, and lying down may alleviate it. Other symptoms are nausea, vomiting, loss of appetite, and low-grade fever.

If the pain is difficult to localize, the ‘pinch test’ can help determine the more painful side

Findings on the abdominal examination that help to confirm the diagnosis include rigidity and tenderness, classically localized to a point two-thirds of the way from the umbilicus to the anterior superior iliac spine. Rebound tenderness is usually present. Up to 25% of cases in some series presented atypically, with variable location and findings on physical examination (eg, bowel irregularities, indigestion, flatulence, generalized malaise). In addition to the physical examination, laboratory testing and imaging (ultrasonography, CT) may aid in confirming the diagnosis of appendicitis or any other cause of the pain.38

VENTRAL HERNIA

Ventral hernia is a bulging of abdominal organs or other tissues through a defect of the musculature of the abdominal wall. Ventral hernia is categorized by its location as epigastric, abdominal, or incisional. An open abdominal procedure is the cause in nearly 10% of cases41; the herniation occurs with weakening of the surgical scar.

Ventral hernia is usually detected on physical examination, and patients may present after noting a bulge in the abdominal wall. Symptoms vary. Some patients have no symptoms, while others have mild abdominal discomfort or severe abdominal pain as well as nausea and vomiting. Imaging with CT, ultrasonography, or magnetic resonance imaging helps confirm the diagnosis. Complications of ventral hernia include incarceration and bowel strangulation.

MEDIAN ARCUATE LIGAMENT SYNDROME

Median arcuate ligament syndrome is a challenging diagnosis and a very rare cause of abdominal pain. It is thought to be caused by celiac artery compression by fibroligamentous bands. Pain fluctuates with respiration and is greater during expiration.

Patients may present with recurrent episodes of crampy postprandial pain that cause them to avoid eating, resulting in weight loss. The pain may be associated with nausea, vomiting, and bloating.

The diagnosis is confirmed by duplex ultrasonography, angiography, or magnetic resonance angiography. Treatment is surgical division of the fibroligamentous band and crus, and this is often done laparascopically. In patients with severe persistent celiac artery stenosis, angioplasty and stenting may be considered.2

CASE CONTINUED

Before the physical examination, our patient identifies the location of her pain. A Carnett test is performed, as for ACNES: the patient is placed in the supine position and is instructed to cross both arms over her chest. In an effort to promote muscle tension, she is asked to elevate her head off the examination table, as if performing a mini sit-up, and as she does this, pressure is applied to the identified tender area. The pain is easily reproduced, further confirming involvement of the abdominal wall rather than the viscera. After this, electromyography shows abnormal findings. The patient is then  referred to the pain management clinic for a diagnostic nerve block.

3. Which of the following is the first-line treatment of ACNES?

  • Local injection of anesthetic
  • Surgical neurectomy

LOCAL INJECTION OF ANESTHETIC

Local injection of anesthetic is the first-line treatment of ACNES.

Figure 1. After the needle is advanced just beyond the fascia and into the rectus abdominis muscle (arrow) under ultrasonographic guidance, 5 mL of 0.25% bupivacaine and 40 mg of triamcinolone are injected into the muscle, providing relief of the pain. An injection of 2% lidocaine may be done as a test block. Higher concentrations of anesthetic are to be avoided, as they may cause a motor block.

Since ACNES is underdiagnosed, the patient may be less likely to be familiar with it. He or she should receive a detailed explanation of the condition and its management; this will help achieve a successful outcome.

Local anesthetic injection is used for both diagnosis and treatment; 2% lidocaine (or an equivalent) or dehydrated (absolute) alcohol or both can eliminate the pain caused by ACNES. The injection is commonly done under ultrasonographic guidance (Figure 1).42

Complete pain relief may be achieved with a single injection, but some patients require up to five injections.

The adjuvant use of corticosteroids in ACNES to reduce inflammation is controversial.

If anesthetic injections bring only minimal pain relief or if the patient has nerve entrapment in a scar, then surgical neurectomy is an option.43 The procedure is performed under local anesthesia, as the patient’s response aids in identifying the specific nerve or nerves involved.

RETURNING TO THE PATIENT

After a long discussion with our patient about ACNES and the treatment options, she  agrees to undergo nerve block in the hope of relieving her pain. She receives a 0.5-mL injection of 2% lidocaine subcutaneously, and within minutes she reports relief of pain. She cannot believe that with a simple injection her pain was relieved. We advise her to return if her pain recurs or if new symptoms arise.

KEEP ACNES IN MIND

ACNES is one of the most commonly misdiagnosed conditions of patients presenting to the outpatient clinic with acute or chronic abdominal pain. This is because the focus is directed to intra-abdominal causes. But if ACNES is kept in consideration from the beginning of the patient encounter, extensive testing, time, and patient anxiety may be reduced significantly. A simple physical examination and the Carnett test aid in raising suspicion of ACNES. If ACNES is confirmed, ultrasonographically guided local anesthetic injection is both diagnostic and therapeutic.

A 31-year-old woman presents to the office with a chief complaint of right mid-abdominal pain that began 1 day ago. She says she did not seek medical attention earlier because she had to be at work that morning and she thought the pain would resolve on its own.

She reports no fever, headache, anorexia, nausea, vomiting, malaise, loss of weight, melena, or changes in bowel habits. She describes the pain as sharp, localized to the right side, and radiating to the vulva upon sitting up. She denies any association of pain with current dietary habits or bowel function. She has no recollection of precipitating or alleviating factors, including the use of analgesics to reduce the pain.

On further discussion, she mentions that 1 year ago she began experiencing chronic abdominal pain, which she says is sometimes exacerbated by coughing, by standing for extended periods of time, and during menses, and is alleviated upon lying down.

She has regular menstrual periods, and her last one ended 7 days ago.

Her surgical history includes two uncomplicated cesarean deliveries. She does not use tobacco, alcohol, or illicit substances. She is not aware of any allergies to drugs or foods.

She appears to be in no acute distress and has been sitting quietly thus far. She seems to have positioned her hand on her abdomen over the corresponding area of pain.

On physical examination, vital signs are within normal limits, and she is alert and oriented to person, place, and time. Her sclerae are anicteric, and the pupils are equal, round, and reactive to light.

Her complete blood cell count, metabolic panel, and initial imaging tests are normal

Cardiovascular and pulmonary examinations are also within normal limits. Examination of the abdomen elicits tenderness and guarding along the lateral border of the rectus abdominis muscle on the right side at the level of umbilicus, with no rebound tenderness or rigidity. The liver and spleen are not enlarged, and no abdominal mass is detected. No skin rash, joint swelling, or peripheral edema is noted. A neurologic examination is normal.

1. With the information provided, which of the following is least likely to be causing her symptoms?

  • Chronic mesenteric ischemia
  • Peptic ulcer
  • Acute cholecystitis
  • Slipping rib syndrome

CHRONIC MESENTERIC ISCHEMIA

Chronic mesenteric ischemia is the least likely diagnosis because the patient lacks risk factors for atherosclerosis and because she does not have postprandial pain, which is pathognomonic for chronic mesenteric ischemia. It is thought to be caused by a decrease in blood flow through the splanchnic vessels.1 Symptoms tend to arise after eating because of a postprandial increase in metabolic demands.1 These patients also often have atherosclerotic risk factors such as hypertension, hyperlipidemia, and smoking causing coronary artery disease, or a history of stroke.

The primary symptom is abdominal pain, most often described as achy, crampy, or spastic episodes of pain, usually occurring within 2 hours of eating.2 Weight loss is common, as patients can develop a fear of eating. Postprandial pain may also be associated with nausea, vomiting, and bloating.

Findings on clinical examination are usually less severe than the actual symptoms. Visceral duplex or multidetector computed tomography (CT) is an excellent tool to detect blood flow in potential stenotic vessels.2

PEPTIC ULCER DISEASE

Peptic ulcer disease is not a likely diagnosis in this patient because she has no history of taking nonsteroidal anti-inflammatory drugs (NSAIDs).

A study of US patients between 1997 and 2007 reported an annual incidence of peptic ulcer disease of 0.05% to 0.19% depending on the method of diagnosis.3 Peptic ulcer is thought to result from increased gastric acid secretion with a resultant inflammatory response, leading to erosion and ulceration.

The most common possible catalysts include Helicobacter pylori infection, NSAIDs, smoking, alcohol use, and hypersecretory states such as Zollinger-Ellison syndrome.4–6 Complications include internal bleeding, perforation causing peritonitis, and penetration to adjacent organs.

Pathophysiology

Peptic ulcer is the result of an increase in the normal level of gastric acid and a decrease in the protective ability of the gastric mucosa.7 Cytoprotection may be lost through a decrease in the products of arachidonic acid metabolism (eg, prostaglandins, which have a protective effect) or an increase in leukotriene B4 (LTB4), which has a damaging effect. Prostaglandins are thought not only to protect the normal gastric mucosa, but also to provide an antisecretory effect.

On the other hand, leukotrienes—specifically LTB4 and LTC4—are proinflammatory agents and can damage the gastric mucosa. NSAIDs enhance the production of leuko­trienes through the 5-lipoxygenase pathway. The ability of LTB4 to cause degranulation and release of lysosomal enzymes may play a vital role in the inflammatory response to NSAIDs.8–10 LTC4 may promote gastric mucosal damage through a reduction of tissue perfusion resulting from the promotion of vascular stasis.8,11,12

Symptoms help differentiate ulcer type

The classic symptom is burning epigastric pain after meals. Pain that occurs immediately after meals is a classic symptom of gastric ulcer. Pain that occurs 2 to 3 hours after meals and that is relieved by food or antacids is a strong indicator of duodenal ulcer.13 Other symptoms include dyspepsia, bloating, distention, heartburn, and chest discomfort.13

Accurate diagnosis is vital in selecting the proper treatment. Diagnostic tests may include H pylori testing, upper-gastrointestinal endoscopy, and radiography with barium swallow.

CHOLECYSTITIS

In cholecystitis, the primary complaint is pain, usually in the right upper quadrant of the abdomen. Patients describe sudden, sharp, and intense pain that radiates to the back or shoulder. Patients may report pain after heavy meals, and some report nausea and vomiting. Cholecystitis is in the differential diagnosis of this patient because of the anatomic location of her pain.

The diagnosis is confirmed by imaging. Abdominal ultrasonography, technetium-99m hepatic iminodiacetic acid scanning, and CT are the most commonly used studies.14

Cholecystitis can be acute or chronic. Acute cholecystitis is categorized as calculous or acalculous. Calculous cholecystitis is multifactorial, but the primary cause is blockage of the cystic duct by gallstones.15 Other factors include irritants such as lysolecithin (released during bile stasis), which can trigger gallbladder inflammation,15–17 and infection.18

When the cystic duct is blocked, bile builds up inside the gallbladder, causing irritation and inflammation of the walls of the gallbladder.14

Acalculous cholecystitis, which resembles calculous cholecystitis but without the gallstones,19 accounts for 2% to 15% of all cases of acute cholecystitis.19,20 It has been observed in hospitalized critically ill patients, but it can also present in an outpatient setting, most often in elderly men with vascular disease.21 Causes include infection, trauma, and tumor obstruction, resulting in endothelial injury, gallbladder stasis, ischemia, and eventually necrosis.14,20,22,23

SLIPPING RIB SYNDROME

Slipping rib syndrome, also known as Tietze syndrome, is believed to be caused by hypermobile costal cartilage. The affected rib slips behind the rib above on contraction of the abdominal wall. This displacement increases the probability of costal nerve impingement and tissue inflammation producing unilateral, sharp, subcostal and upper-abdominal pain.

In this patient, slipping rib syndrome is a possible diagnosis because of the location of the pain and because the pain described by the patient is highly suggestive of neuropathic pain.

Slipping rib syndrome is diagnosed clinically by a “hooking” maneuver: the clinician hooks his or her fingers at the patient’s subcostal area, reproducing the pain by movement of the ribs anteriorly.24 When this test is performed in our patient the result is negative, ruling out slipping rib syndrome.

THE WORKUP CONTINUES

A complete blood cell count and comprehensive metabolic panel are within normal limits. Abdominal duplex ultrasonography reveals no celiac or mesenteric occlusions, thus ruling out chronic mesenteric ischemia.

Noncontrast CT shows no renal or ureteric stones and no evidence of bleeding in the urinary tract. CT with contrast shows no bowel distention, no evidence of hernia, and a normal appendix and ovaries.

2. After exclusion of the previous choices, which of the following is the most likely cause of her symptoms?

  • Anterior cutaneous nerve entrapment syndrome (ACNES)
  • Ovarian cyst
  • Renal stones
  • Appendicitis
  • Ventral hernia
  • Median arcuate ligament syndrome
 

 

ANTERIOR CUTANEOUS NERVE ENTRAPMENT SYNDROME

ACNES is the most likely diagnosis. A study published in 2013 indicated that many cases of functional abdominal pain may actually be undiagnosed cases of chronic abdominal wall pain such as ACNES.25 The condition, first described in 1972,26 is thought to be caused by thoracic cutaneous intercostal nerve entrapment between the abdominal muscles, causing pain at the point of entrapment.

The patient may present with pain that is either acute or chronic. Acute pain is localized more on the right side close to an old scar, or at the outer edge of the rectus abdominis muscle. The pain may vary from dull to burning to sharp; it can radiate horizontally in the upper half of the abdomen or obliquely in the lower half of the abdomen with movements such as twisting and sitting up.27

Despite the acute pain, patients are able to carry on daily functions. The pain may be alleviated by lying down.

The pain may be misdiagnosed as gynecologic or renal. In younger men, the pain may raise concern about hernia, and in older patients, cancer.27 Patients may complain of chronic intermittent pain, usually unilateral, and to a lesser extent bilateral.27

The anatomic location of the pain usually reflects the intercostal nerve involved. The pain is not related to eating or to bowel movements.25 Some patients report exacerbation upon coughing or standing, during menses, and with use of oral contraceptives.28,29 When inquiring about surgical history, it is common to find that the patient has had multiple abdominal surgical procedures.

On examination, the patient has nondistressing pain, with a hand often placed over the painful area.27 On firm palpation, a tender spot of less than 2 cm can be detected.

The diagnosis can be confirmed with a positive Carnett test. The patient lies supine on the examination table with the arms crossed over the chest, then elevates the head or the feet to tense the abdominal muscles.26,27 If doing so reproduces the pain (ie, a positive test), this increases the suspicion of ACNES; if the pain decreases or is not reproducible, an intra-abdominal cause is more likely.

A positive Carnett test helps rule out visceral involvement

If the pain is difficult to localize, the “pinch test” can be done by using the thumb and index finger to pinch and lift the skin of the abdomen, including the subcutaneous layer of fat, first on one side and then on the other. This helps determine the side with greater pain.27

OVARIAN CYSTS

Ovarian cysts are fluid-filled sacs on the surface of or within the ovary. They are often benign and require no intervention. However, 5% to 10% of US women with a suspicious ovarian mass undergo a surgical procedure, and 13% to 21% of these are found to have a malignancy.30,31

Ovarian cysts are usually painless unless complicated by rupture or bleeding. Patients who present with pain describe it as dull and aching and in the abdomen or pelvis. In rare cases, ovarian cysts can be large enough to cause pain from torsion. Other symptoms may include delayed menses and bleeding outside of the menstrual period.32–34

Ovarian cysts are thought to be caused by hormonal changes during the menstrual cycle. They can be detected during pelvic examination or during pelvic ultrasonography. Cysts that are primarily fluid-filled are generally benign and require no intervention. On the other hand, cysts composed of solid material require intervention.

Treatment depends on several factors, including size and type of cyst, the patient’s age, and whether torsion is present. Treatment can range from observation to medical or surgical management. Laparoscopic surgery is commonly used when surgical treatment is warranted.

RENAL STONES

From 10% to 15% of US adults develop a kidney stone at some time during their life.35 There is no single cause, but one factor that promotes stone formation is a greater amount of crystal-forming substances in the urine, such as calcium, oxalate, and uric acid.36 Most renal stones are calcium oxalate, uric acid, struvite, or cysteine.

Symptoms arise when the stone moves within the urinary tract. Patients present to the emergency room in severe distress, usually with flank pain that radiates to the lower abdomen or groin. The pain is episodic, fluctuates in intensity, and may present with dysuria, frequency, or urgency. It is also associated with nausea and vomiting.37

Renal stones are diagnosed through a series of laboratory and imaging studies. Imaging studies include plain radiography (which can miss small stones), renal sonography, and computed tomography without contrast.

APPENDICITIS

In the United States, the lifetime risk of developing appendicitis is 8.6% in men and 6.7% in women.38 Appendicitis is one of the most common reasons for emergency surgery.

Appendicitis is thought to result from obstruction by fecal matter blocking the opening of the appendix or from a viral infection (eg, with an adenovirus).39,40 The resulting bacterial growth can cause the appendix to become inflamed and purulent.

Patients typically present with umbilical or epigastric pain radiating to the right lower quadrant of the abdomen. Over time, the pain becomes sharper. Certain movements can exacerbate the pain, and lying down may alleviate it. Other symptoms are nausea, vomiting, loss of appetite, and low-grade fever.

If the pain is difficult to localize, the ‘pinch test’ can help determine the more painful side

Findings on the abdominal examination that help to confirm the diagnosis include rigidity and tenderness, classically localized to a point two-thirds of the way from the umbilicus to the anterior superior iliac spine. Rebound tenderness is usually present. Up to 25% of cases in some series presented atypically, with variable location and findings on physical examination (eg, bowel irregularities, indigestion, flatulence, generalized malaise). In addition to the physical examination, laboratory testing and imaging (ultrasonography, CT) may aid in confirming the diagnosis of appendicitis or any other cause of the pain.38

VENTRAL HERNIA

Ventral hernia is a bulging of abdominal organs or other tissues through a defect of the musculature of the abdominal wall. Ventral hernia is categorized by its location as epigastric, abdominal, or incisional. An open abdominal procedure is the cause in nearly 10% of cases41; the herniation occurs with weakening of the surgical scar.

Ventral hernia is usually detected on physical examination, and patients may present after noting a bulge in the abdominal wall. Symptoms vary. Some patients have no symptoms, while others have mild abdominal discomfort or severe abdominal pain as well as nausea and vomiting. Imaging with CT, ultrasonography, or magnetic resonance imaging helps confirm the diagnosis. Complications of ventral hernia include incarceration and bowel strangulation.

MEDIAN ARCUATE LIGAMENT SYNDROME

Median arcuate ligament syndrome is a challenging diagnosis and a very rare cause of abdominal pain. It is thought to be caused by celiac artery compression by fibroligamentous bands. Pain fluctuates with respiration and is greater during expiration.

Patients may present with recurrent episodes of crampy postprandial pain that cause them to avoid eating, resulting in weight loss. The pain may be associated with nausea, vomiting, and bloating.

The diagnosis is confirmed by duplex ultrasonography, angiography, or magnetic resonance angiography. Treatment is surgical division of the fibroligamentous band and crus, and this is often done laparascopically. In patients with severe persistent celiac artery stenosis, angioplasty and stenting may be considered.2

CASE CONTINUED

Before the physical examination, our patient identifies the location of her pain. A Carnett test is performed, as for ACNES: the patient is placed in the supine position and is instructed to cross both arms over her chest. In an effort to promote muscle tension, she is asked to elevate her head off the examination table, as if performing a mini sit-up, and as she does this, pressure is applied to the identified tender area. The pain is easily reproduced, further confirming involvement of the abdominal wall rather than the viscera. After this, electromyography shows abnormal findings. The patient is then  referred to the pain management clinic for a diagnostic nerve block.

3. Which of the following is the first-line treatment of ACNES?

  • Local injection of anesthetic
  • Surgical neurectomy

LOCAL INJECTION OF ANESTHETIC

Local injection of anesthetic is the first-line treatment of ACNES.

Figure 1. After the needle is advanced just beyond the fascia and into the rectus abdominis muscle (arrow) under ultrasonographic guidance, 5 mL of 0.25% bupivacaine and 40 mg of triamcinolone are injected into the muscle, providing relief of the pain. An injection of 2% lidocaine may be done as a test block. Higher concentrations of anesthetic are to be avoided, as they may cause a motor block.

Since ACNES is underdiagnosed, the patient may be less likely to be familiar with it. He or she should receive a detailed explanation of the condition and its management; this will help achieve a successful outcome.

Local anesthetic injection is used for both diagnosis and treatment; 2% lidocaine (or an equivalent) or dehydrated (absolute) alcohol or both can eliminate the pain caused by ACNES. The injection is commonly done under ultrasonographic guidance (Figure 1).42

Complete pain relief may be achieved with a single injection, but some patients require up to five injections.

The adjuvant use of corticosteroids in ACNES to reduce inflammation is controversial.

If anesthetic injections bring only minimal pain relief or if the patient has nerve entrapment in a scar, then surgical neurectomy is an option.43 The procedure is performed under local anesthesia, as the patient’s response aids in identifying the specific nerve or nerves involved.

RETURNING TO THE PATIENT

After a long discussion with our patient about ACNES and the treatment options, she  agrees to undergo nerve block in the hope of relieving her pain. She receives a 0.5-mL injection of 2% lidocaine subcutaneously, and within minutes she reports relief of pain. She cannot believe that with a simple injection her pain was relieved. We advise her to return if her pain recurs or if new symptoms arise.

KEEP ACNES IN MIND

ACNES is one of the most commonly misdiagnosed conditions of patients presenting to the outpatient clinic with acute or chronic abdominal pain. This is because the focus is directed to intra-abdominal causes. But if ACNES is kept in consideration from the beginning of the patient encounter, extensive testing, time, and patient anxiety may be reduced significantly. A simple physical examination and the Carnett test aid in raising suspicion of ACNES. If ACNES is confirmed, ultrasonographically guided local anesthetic injection is both diagnostic and therapeutic.

References
  1. American Gastroenterological Association Medical Position Statement: Guidelines On Intestinal Ischemia. Gastroenterology 2000; 118:951–953.
  2. Bobadilla JL. Mesenteric ischemia. Surg Clin North Am 2013; 93:925–940.
  3. Sung JJ, Kuipers EJ, El-Serag HB. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther 2009; 29:938–946.
  4. Najm WI. Peptic ulcer disease. Prim Care 2011; 38:383–394.
  5. Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet 2009; 374:1449–1461.
  6. Chan FK, Leung WK. Peptic-ulcer disease. Lancet 2002; 360:933–941.
  7. Bright-Asare P, Habte T, Yirgou B, Benjamin J. Prostaglandins, H2-receptor antagonists and peptic ulcer disease. Drugs 1988; 35(suppl 3):1–9.
  8. Hudson N, Balsitis M, Everitt S, Hawkey CJ. Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993; 34:742–747.
  9. Ford-Hutchinson AW, Bray MA, Doig MV, Shipley ME, Smith MJ. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 1980; 286:264–265.
  10. Bokoch GM, Reed PW. Effect of various lipoxygenase metabolites of arachidonic acid on degranulation of polymorphonuclear leukocytes. J  Biol Chem 1981; 256:5317–5320.
  11. Whittle BJ, Oren-Wolman N, Guth PH. Gastric vasoconstrictor actions of leukotriene C4, PGF2 alpha, and thromboxane mimetic U-46619 on rat submucosal microcirculation in vivo. Am J Physiol 1985; 248:G580–G586.
  12. Pihan G, Rogers C, Szabo S. Vascular injury in acute gastric mucosal damage. Mediatory role of leukotrienes. Dig Dis Sci 1988; 33:625–632.
  13. Ramakrishnan K, Salinas RC. Peptic ulcer disease. Am Fam Physician 2007; 76:1005–1012.
  14. Parmet S, Lynm C, Glass RM. JAMA patient page. Acute cholecystitis. JAMA 2003; 289:124.
  15. Roslyn JJ, DenBesten L, Thompson JE Jr, Silverman BF. Roles of lithogenic bile and cystic duct occlusion in the pathogenesis of acute cholecystitis. Am J Surg 1980; 140:126–130.
  16. Kaminski DL. Arachidonic acid metabolites in hepatobiliary physiology and disease. Gastroenterology 1989; 97:781–792.
  17. Jivegård L, Thornell E, Svanvik J. Pathophysiology of acute obstructive cholecystitis: implications for non-operative management. Br J Surg 1987; 74:1084–1086.
  18. Csendes A, Burdiles P, Maluenda F, Diaz JC, Csendes P, Mitru N. Simultaneous bacteriologic assessment of bile from gallbladder and common bile duct in control subjects and patients with gallstones and common duct stones. Arch Surg 1996; 131:389–394.
  19. Barie PS, Fischer E. Acute acalculous cholecystitis. J Am Coll Surg 1995; 180:232–244.
  20. Shapiro MJ, Luchtefeld WB, Kurzweil S, Kaminski DL, Durham RM, Mazuski JE. Acute acalculous cholecystitis in the critically ill. Am Surg 1994; 60:335–339.
  21. Savoca PE, Longo WE, Zucker KA, McMillen MM, Modlin IM. The increasing prevalence of acalculous cholecystitis in outpatients. Results of a 7-year study. Ann Surg 1990; 211:433–437.
  22. Gofrit O, Eid A, Pikarsky A, Lebensart PD, Pizov G, Rivkind A. Cholesterol embolisation causing chronic acalculous cholecystitis. Eur J Surg 1996; 162:243–245.
  23. McChesney JA, Northup PG, Bickston SJ. Acute acalculous cholecystitis associated with systemic sepsis and visceral arterial hypoperfusion: a case series and review of pathophysiology. Dig Dis Sci 2003; 48:1960–1967.
  24. Aeschlimann A, Kahn MF. Tietze’s syndrome: a critical review. Clin Exp Rheumatol 1990; 8:407–412.
  25. van Assen T, de Jager-Kievit JW, Scheltinga MR, Roumen RM. Chronic abdominal wall pain misdiagnosed as functional abdominal pain. J Am Board Fam Med 2013; 26:738–744.
  26. Akhnikh S, de Korte N, de Winter P. Anterior cutaneous nerve entrapment syndrome (ACNES): the forgotten diagnosis. Eur J Pediatr 2014; 173:445–449.
  27. Applegate WV. Abdominal cutaneous nerve entrapment syndrome (ACNES): a commonly overlooked cause of abdominal pain. Perm J 2002; 6:20–27.
  28. Grover M. UNC Center for Functional GI & Motility Disorders. Chronic abdominal wall pain: a missed diagnosis. www.med.unc.edu/ibs/files/educational-gi-handouts/Chronic%20Abdominal%20Pain.pdf. Accessed September 9, 2015.
  29. Greenbaum D, Dawson F, Watson R. Chronic abdominal wall pain (CAWP): a common but frequently overlooked disorder. Poster presented at the World Congress of Gastroenterology, Sydney, Australia, August 26–31, 1990.
  30. National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up. Gynecol Oncol 1994; 55:S4–S14.
  31. Koonings PP, Campbell K, Mishell DR Jr, Grimes DA. Relative frequency of primary ovarian neoplasms: a 10-year review. Obstet Gynecol 1989; 74:921–926.
  32. Givens V, Mitchell GE, Harraway-Smith C, Reddy A, Maness DL. Diagnosis and management of adnexal masses. Am Fam Physician 2009; 80:815–820.
  33. Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer 2000; 89:2068–2075.
  34. Friedman GD, Skilling JS, Udaltsova NV, Smith LH. Early symptoms of ovarian cancer: a case-control study without recall bias. Fam Pract 2005; 22:548–553.
  35. Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int 2003; 63:1817–1823.
  36. Worcester EM, Coe FL. Clinical practice. Calcium kidney stones. N Engl J Med 2010; 363:954–963.
  37. Miller NL, Lingeman JE. Management of kidney stones. BMJ 2007; 334:468–472.
  38. Lewis SR, Mahony PJ, Simpson J. Appendicitis. BMJ 2011; 343:d5976.
  39. Lamps LW. Infectious causes of appendicitis. Infect Dis Clin North Am 2010; 24:995–1018.
  40. Reif RM. Viral appendicitis. Hum Pathol 1981; 12:193–196.
  41. Akkary E, Panait L, Roberts K, Duffy A, Bell R. Sutureless laparoscopic ventral hernia repair in obese patients. JSLS 2011; 15:154–159.
  42. Boelens OB, Scheltinga MR, Houterman S, Roumen RM. Randomized clinical trial of trigger point infiltration with lidocaine to diagnose anterior cutaneous nerve entrapment syndrome. Br J Surg 2013; 100:217–221.
  43. Boelens OB, Scheltinga MR, Houterman S, Roumen RM. Management of anterior cutaneous nerve entrapment syndrome in a cohort of 139 patients. Ann Surg 2011; 254:1054–1058.
References
  1. American Gastroenterological Association Medical Position Statement: Guidelines On Intestinal Ischemia. Gastroenterology 2000; 118:951–953.
  2. Bobadilla JL. Mesenteric ischemia. Surg Clin North Am 2013; 93:925–940.
  3. Sung JJ, Kuipers EJ, El-Serag HB. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther 2009; 29:938–946.
  4. Najm WI. Peptic ulcer disease. Prim Care 2011; 38:383–394.
  5. Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet 2009; 374:1449–1461.
  6. Chan FK, Leung WK. Peptic-ulcer disease. Lancet 2002; 360:933–941.
  7. Bright-Asare P, Habte T, Yirgou B, Benjamin J. Prostaglandins, H2-receptor antagonists and peptic ulcer disease. Drugs 1988; 35(suppl 3):1–9.
  8. Hudson N, Balsitis M, Everitt S, Hawkey CJ. Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993; 34:742–747.
  9. Ford-Hutchinson AW, Bray MA, Doig MV, Shipley ME, Smith MJ. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 1980; 286:264–265.
  10. Bokoch GM, Reed PW. Effect of various lipoxygenase metabolites of arachidonic acid on degranulation of polymorphonuclear leukocytes. J  Biol Chem 1981; 256:5317–5320.
  11. Whittle BJ, Oren-Wolman N, Guth PH. Gastric vasoconstrictor actions of leukotriene C4, PGF2 alpha, and thromboxane mimetic U-46619 on rat submucosal microcirculation in vivo. Am J Physiol 1985; 248:G580–G586.
  12. Pihan G, Rogers C, Szabo S. Vascular injury in acute gastric mucosal damage. Mediatory role of leukotrienes. Dig Dis Sci 1988; 33:625–632.
  13. Ramakrishnan K, Salinas RC. Peptic ulcer disease. Am Fam Physician 2007; 76:1005–1012.
  14. Parmet S, Lynm C, Glass RM. JAMA patient page. Acute cholecystitis. JAMA 2003; 289:124.
  15. Roslyn JJ, DenBesten L, Thompson JE Jr, Silverman BF. Roles of lithogenic bile and cystic duct occlusion in the pathogenesis of acute cholecystitis. Am J Surg 1980; 140:126–130.
  16. Kaminski DL. Arachidonic acid metabolites in hepatobiliary physiology and disease. Gastroenterology 1989; 97:781–792.
  17. Jivegård L, Thornell E, Svanvik J. Pathophysiology of acute obstructive cholecystitis: implications for non-operative management. Br J Surg 1987; 74:1084–1086.
  18. Csendes A, Burdiles P, Maluenda F, Diaz JC, Csendes P, Mitru N. Simultaneous bacteriologic assessment of bile from gallbladder and common bile duct in control subjects and patients with gallstones and common duct stones. Arch Surg 1996; 131:389–394.
  19. Barie PS, Fischer E. Acute acalculous cholecystitis. J Am Coll Surg 1995; 180:232–244.
  20. Shapiro MJ, Luchtefeld WB, Kurzweil S, Kaminski DL, Durham RM, Mazuski JE. Acute acalculous cholecystitis in the critically ill. Am Surg 1994; 60:335–339.
  21. Savoca PE, Longo WE, Zucker KA, McMillen MM, Modlin IM. The increasing prevalence of acalculous cholecystitis in outpatients. Results of a 7-year study. Ann Surg 1990; 211:433–437.
  22. Gofrit O, Eid A, Pikarsky A, Lebensart PD, Pizov G, Rivkind A. Cholesterol embolisation causing chronic acalculous cholecystitis. Eur J Surg 1996; 162:243–245.
  23. McChesney JA, Northup PG, Bickston SJ. Acute acalculous cholecystitis associated with systemic sepsis and visceral arterial hypoperfusion: a case series and review of pathophysiology. Dig Dis Sci 2003; 48:1960–1967.
  24. Aeschlimann A, Kahn MF. Tietze’s syndrome: a critical review. Clin Exp Rheumatol 1990; 8:407–412.
  25. van Assen T, de Jager-Kievit JW, Scheltinga MR, Roumen RM. Chronic abdominal wall pain misdiagnosed as functional abdominal pain. J Am Board Fam Med 2013; 26:738–744.
  26. Akhnikh S, de Korte N, de Winter P. Anterior cutaneous nerve entrapment syndrome (ACNES): the forgotten diagnosis. Eur J Pediatr 2014; 173:445–449.
  27. Applegate WV. Abdominal cutaneous nerve entrapment syndrome (ACNES): a commonly overlooked cause of abdominal pain. Perm J 2002; 6:20–27.
  28. Grover M. UNC Center for Functional GI & Motility Disorders. Chronic abdominal wall pain: a missed diagnosis. www.med.unc.edu/ibs/files/educational-gi-handouts/Chronic%20Abdominal%20Pain.pdf. Accessed September 9, 2015.
  29. Greenbaum D, Dawson F, Watson R. Chronic abdominal wall pain (CAWP): a common but frequently overlooked disorder. Poster presented at the World Congress of Gastroenterology, Sydney, Australia, August 26–31, 1990.
  30. National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up. Gynecol Oncol 1994; 55:S4–S14.
  31. Koonings PP, Campbell K, Mishell DR Jr, Grimes DA. Relative frequency of primary ovarian neoplasms: a 10-year review. Obstet Gynecol 1989; 74:921–926.
  32. Givens V, Mitchell GE, Harraway-Smith C, Reddy A, Maness DL. Diagnosis and management of adnexal masses. Am Fam Physician 2009; 80:815–820.
  33. Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer 2000; 89:2068–2075.
  34. Friedman GD, Skilling JS, Udaltsova NV, Smith LH. Early symptoms of ovarian cancer: a case-control study without recall bias. Fam Pract 2005; 22:548–553.
  35. Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int 2003; 63:1817–1823.
  36. Worcester EM, Coe FL. Clinical practice. Calcium kidney stones. N Engl J Med 2010; 363:954–963.
  37. Miller NL, Lingeman JE. Management of kidney stones. BMJ 2007; 334:468–472.
  38. Lewis SR, Mahony PJ, Simpson J. Appendicitis. BMJ 2011; 343:d5976.
  39. Lamps LW. Infectious causes of appendicitis. Infect Dis Clin North Am 2010; 24:995–1018.
  40. Reif RM. Viral appendicitis. Hum Pathol 1981; 12:193–196.
  41. Akkary E, Panait L, Roberts K, Duffy A, Bell R. Sutureless laparoscopic ventral hernia repair in obese patients. JSLS 2011; 15:154–159.
  42. Boelens OB, Scheltinga MR, Houterman S, Roumen RM. Randomized clinical trial of trigger point infiltration with lidocaine to diagnose anterior cutaneous nerve entrapment syndrome. Br J Surg 2013; 100:217–221.
  43. Boelens OB, Scheltinga MR, Houterman S, Roumen RM. Management of anterior cutaneous nerve entrapment syndrome in a cohort of 139 patients. Ann Surg 2011; 254:1054–1058.
Issue
Cleveland Clinic Journal of Medicine - 83(1)
Issue
Cleveland Clinic Journal of Medicine - 83(1)
Page Number
29-35
Page Number
29-35
Publications
Publications
Topics
Article Type
Display Headline
Not all abdominal pain is gastrointestinal
Display Headline
Not all abdominal pain is gastrointestinal
Legacy Keywords
abdominal pain, mesenteric ischemia, peptic ulcer, cholecystitis, slipping rib syndrome, nerve entrapment, anterior cutaneous nerve entrapment syndrome, ACNES, Mena Boules, Madonna Michael, Julietta Chang, Bruce Vrooman, Matthew Kroh, Maged Rizk
Legacy Keywords
abdominal pain, mesenteric ischemia, peptic ulcer, cholecystitis, slipping rib syndrome, nerve entrapment, anterior cutaneous nerve entrapment syndrome, ACNES, Mena Boules, Madonna Michael, Julietta Chang, Bruce Vrooman, Matthew Kroh, Maged Rizk
Sections
Disallow All Ads
Alternative CME
Article PDF Media

Eventration of the diaphragm presenting as spontaneous pneumothorax

Article Type
Changed
Display Headline
Eventration of the diaphragm presenting as spontaneous pneumothorax

A 25-year-old man with a 2-day history of upper respiratory tract infection presents to the emergency department with the sudden onset of right-sided back and chest pain and shortness of breath after a severe coughing fit.

He is morbidly obese, is a long-time smoker, and has had recurrent exacerbations of asthma with frequent upper respiratory tract infections. He has no history of recent trauma.

A review of systems reveals no significant impairment in exercise tolerance. He has been able to continue doing manual labor at his job as a railroad worker.

Figure 1. Plain radiography shows a large right pneumothorax and an elevated right diaphragm.

Figure 2. Thoracic computed tomography shows right anterior apical pneumothorax with atelectatic and hypoplastic lung in a cross-sectional view (A). A coronal view (B) shows significant elevation of the right hemidiaphragm, with fat, bowel, and kidney within the right hemithorax.

Radiography shows a large right pneumothorax and an elevated right diaphragm (Figure 1). Computed tomography (CT) (Figure 2) reveals a right anterior apical pneumothorax with hypoplastic lung and significant elevation of the right diaphragm with fat, bowel, and kidney within the right thorax. He is hemodynamically stable and shows no signs of bowel obstruction.

The physical examination is normal except for diminished breath sounds on the right side. He is diagnosed with congenital diaphragmatic hernia and spontaneous pneumothorax. A 10-F locking pigtail catheter is inserted under CT guidance, leading to complete resolution of the pneumothorax. He is discharged home the next day with a plan for elective repair of the hernia.

Two months later, he returns for scheduled right thoracotomy to repair the hernia. However, while preparing the chest cavity, the surgeon finds no diaphragmatic hernia and no intra-abdominal content—but rather, a severely elevated and thinned-out diaphragm with uninterrupted continuity. The diagnosis is changed to congenital diaphragmatic eventration, and plication of the diaphragm is performed with a series of interrupted, pledgeted polypropylene sutures.

CONGENITAL EVENTRATION OF THE DIAPHRAGM

Congenital diaphragmatic eventration is a rare developmental defect of the central, muscular portion of the diaphragm. The true prevalence is not known, but early reports identified this condition in less than 0.1% of adult.1

Symptomatic patients usually experience dyspnea secondary to ventilation-perfusion mismatch resulting from chronic atelectasis and lung hypoplasia, as well as impaired ventilation resulting from the limited caudal migration of the diaphragm.2,3 Increased susceptibility to recurrent upper respiratory tract infections and pneumonia is also a common feature.

Although rare, spontaneous pneumothorax can develop in patients such as ours, whose lengthy history of smoking and asthma predisposed him to the development of emphysema-like blebs and bullae and to subsequent rupture of blebs brought on by vigorous coughing that caused an involuntary Valsalva maneuver.4

As in our patient, distinguishing congenital diaphragmatic eventration from hernia preoperatively can be difficult with plain chest radiography. Spiral CT with multiplanar reconstruction or with magnetic resonance imaging can help establish the diagnosis.3 However, a severely attenuated diaphragm can be difficult to visualize on CT, as in our patient, leading to a presumptive diagnosis of diaphragmatic hernia. In such situations, the diagnosis of eventration can only be made intraoperatively.

Surgical repair is indicated only for patients with symptoms. Other potential causes of the symptoms should first be ruled out, however, including primary pulmonary disease, cardiac dysfunction, and morbid obesity.

References
  1. Chin EF, Lynn RB. Surgery of eventration of the diaphragm. J Thorac Surg 1956; 32:6–14.
  2. Ridyard JB, Stewart RM. Regional lung function in unilateral diaphragmatic paralysis. Thorax 1976; 31:438–442.
  3. Shen C, Che G. Congenital eventration of hemidiaphragm in an adult. Ann Thorac Surg 2012; 94:e137–e139.
  4. Porpodis K, Zarogoulidis P, Spyratos D, et al. Pneumothorax and asthma. J Thorac Dis 2014; 6(suppl 1):S152–S161.
Article PDF
Author and Disclosure Information

Pauline Go, MD
Department of Surgery, Henry Ford Hospital, Detroit, MI

Zane Hammoud, MD
Division of Thoracic Surgery, Henry Ford Hospital, Detroit, MI

Address: Pauline Go, MD, Department of Surgery, CFP-127, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202; e-mail: pgo1@hfhs.org

Dr. Hammoud has disclosed consulting for Ethicon Inc.

Issue
Cleveland Clinic Journal of Medicine - 83(1)
Publications
Topics
Page Number
19-20
Legacy Keywords
diaphragm, eventration, pneumothorax, hernia, Pauline Go, Zane Hammoud
Sections
Author and Disclosure Information

Pauline Go, MD
Department of Surgery, Henry Ford Hospital, Detroit, MI

Zane Hammoud, MD
Division of Thoracic Surgery, Henry Ford Hospital, Detroit, MI

Address: Pauline Go, MD, Department of Surgery, CFP-127, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202; e-mail: pgo1@hfhs.org

Dr. Hammoud has disclosed consulting for Ethicon Inc.

Author and Disclosure Information

Pauline Go, MD
Department of Surgery, Henry Ford Hospital, Detroit, MI

Zane Hammoud, MD
Division of Thoracic Surgery, Henry Ford Hospital, Detroit, MI

Address: Pauline Go, MD, Department of Surgery, CFP-127, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202; e-mail: pgo1@hfhs.org

Dr. Hammoud has disclosed consulting for Ethicon Inc.

Article PDF
Article PDF
Related Articles

A 25-year-old man with a 2-day history of upper respiratory tract infection presents to the emergency department with the sudden onset of right-sided back and chest pain and shortness of breath after a severe coughing fit.

He is morbidly obese, is a long-time smoker, and has had recurrent exacerbations of asthma with frequent upper respiratory tract infections. He has no history of recent trauma.

A review of systems reveals no significant impairment in exercise tolerance. He has been able to continue doing manual labor at his job as a railroad worker.

Figure 1. Plain radiography shows a large right pneumothorax and an elevated right diaphragm.

Figure 2. Thoracic computed tomography shows right anterior apical pneumothorax with atelectatic and hypoplastic lung in a cross-sectional view (A). A coronal view (B) shows significant elevation of the right hemidiaphragm, with fat, bowel, and kidney within the right hemithorax.

Radiography shows a large right pneumothorax and an elevated right diaphragm (Figure 1). Computed tomography (CT) (Figure 2) reveals a right anterior apical pneumothorax with hypoplastic lung and significant elevation of the right diaphragm with fat, bowel, and kidney within the right thorax. He is hemodynamically stable and shows no signs of bowel obstruction.

The physical examination is normal except for diminished breath sounds on the right side. He is diagnosed with congenital diaphragmatic hernia and spontaneous pneumothorax. A 10-F locking pigtail catheter is inserted under CT guidance, leading to complete resolution of the pneumothorax. He is discharged home the next day with a plan for elective repair of the hernia.

Two months later, he returns for scheduled right thoracotomy to repair the hernia. However, while preparing the chest cavity, the surgeon finds no diaphragmatic hernia and no intra-abdominal content—but rather, a severely elevated and thinned-out diaphragm with uninterrupted continuity. The diagnosis is changed to congenital diaphragmatic eventration, and plication of the diaphragm is performed with a series of interrupted, pledgeted polypropylene sutures.

CONGENITAL EVENTRATION OF THE DIAPHRAGM

Congenital diaphragmatic eventration is a rare developmental defect of the central, muscular portion of the diaphragm. The true prevalence is not known, but early reports identified this condition in less than 0.1% of adult.1

Symptomatic patients usually experience dyspnea secondary to ventilation-perfusion mismatch resulting from chronic atelectasis and lung hypoplasia, as well as impaired ventilation resulting from the limited caudal migration of the diaphragm.2,3 Increased susceptibility to recurrent upper respiratory tract infections and pneumonia is also a common feature.

Although rare, spontaneous pneumothorax can develop in patients such as ours, whose lengthy history of smoking and asthma predisposed him to the development of emphysema-like blebs and bullae and to subsequent rupture of blebs brought on by vigorous coughing that caused an involuntary Valsalva maneuver.4

As in our patient, distinguishing congenital diaphragmatic eventration from hernia preoperatively can be difficult with plain chest radiography. Spiral CT with multiplanar reconstruction or with magnetic resonance imaging can help establish the diagnosis.3 However, a severely attenuated diaphragm can be difficult to visualize on CT, as in our patient, leading to a presumptive diagnosis of diaphragmatic hernia. In such situations, the diagnosis of eventration can only be made intraoperatively.

Surgical repair is indicated only for patients with symptoms. Other potential causes of the symptoms should first be ruled out, however, including primary pulmonary disease, cardiac dysfunction, and morbid obesity.

A 25-year-old man with a 2-day history of upper respiratory tract infection presents to the emergency department with the sudden onset of right-sided back and chest pain and shortness of breath after a severe coughing fit.

He is morbidly obese, is a long-time smoker, and has had recurrent exacerbations of asthma with frequent upper respiratory tract infections. He has no history of recent trauma.

A review of systems reveals no significant impairment in exercise tolerance. He has been able to continue doing manual labor at his job as a railroad worker.

Figure 1. Plain radiography shows a large right pneumothorax and an elevated right diaphragm.

Figure 2. Thoracic computed tomography shows right anterior apical pneumothorax with atelectatic and hypoplastic lung in a cross-sectional view (A). A coronal view (B) shows significant elevation of the right hemidiaphragm, with fat, bowel, and kidney within the right hemithorax.

Radiography shows a large right pneumothorax and an elevated right diaphragm (Figure 1). Computed tomography (CT) (Figure 2) reveals a right anterior apical pneumothorax with hypoplastic lung and significant elevation of the right diaphragm with fat, bowel, and kidney within the right thorax. He is hemodynamically stable and shows no signs of bowel obstruction.

The physical examination is normal except for diminished breath sounds on the right side. He is diagnosed with congenital diaphragmatic hernia and spontaneous pneumothorax. A 10-F locking pigtail catheter is inserted under CT guidance, leading to complete resolution of the pneumothorax. He is discharged home the next day with a plan for elective repair of the hernia.

Two months later, he returns for scheduled right thoracotomy to repair the hernia. However, while preparing the chest cavity, the surgeon finds no diaphragmatic hernia and no intra-abdominal content—but rather, a severely elevated and thinned-out diaphragm with uninterrupted continuity. The diagnosis is changed to congenital diaphragmatic eventration, and plication of the diaphragm is performed with a series of interrupted, pledgeted polypropylene sutures.

CONGENITAL EVENTRATION OF THE DIAPHRAGM

Congenital diaphragmatic eventration is a rare developmental defect of the central, muscular portion of the diaphragm. The true prevalence is not known, but early reports identified this condition in less than 0.1% of adult.1

Symptomatic patients usually experience dyspnea secondary to ventilation-perfusion mismatch resulting from chronic atelectasis and lung hypoplasia, as well as impaired ventilation resulting from the limited caudal migration of the diaphragm.2,3 Increased susceptibility to recurrent upper respiratory tract infections and pneumonia is also a common feature.

Although rare, spontaneous pneumothorax can develop in patients such as ours, whose lengthy history of smoking and asthma predisposed him to the development of emphysema-like blebs and bullae and to subsequent rupture of blebs brought on by vigorous coughing that caused an involuntary Valsalva maneuver.4

As in our patient, distinguishing congenital diaphragmatic eventration from hernia preoperatively can be difficult with plain chest radiography. Spiral CT with multiplanar reconstruction or with magnetic resonance imaging can help establish the diagnosis.3 However, a severely attenuated diaphragm can be difficult to visualize on CT, as in our patient, leading to a presumptive diagnosis of diaphragmatic hernia. In such situations, the diagnosis of eventration can only be made intraoperatively.

Surgical repair is indicated only for patients with symptoms. Other potential causes of the symptoms should first be ruled out, however, including primary pulmonary disease, cardiac dysfunction, and morbid obesity.

References
  1. Chin EF, Lynn RB. Surgery of eventration of the diaphragm. J Thorac Surg 1956; 32:6–14.
  2. Ridyard JB, Stewart RM. Regional lung function in unilateral diaphragmatic paralysis. Thorax 1976; 31:438–442.
  3. Shen C, Che G. Congenital eventration of hemidiaphragm in an adult. Ann Thorac Surg 2012; 94:e137–e139.
  4. Porpodis K, Zarogoulidis P, Spyratos D, et al. Pneumothorax and asthma. J Thorac Dis 2014; 6(suppl 1):S152–S161.
References
  1. Chin EF, Lynn RB. Surgery of eventration of the diaphragm. J Thorac Surg 1956; 32:6–14.
  2. Ridyard JB, Stewart RM. Regional lung function in unilateral diaphragmatic paralysis. Thorax 1976; 31:438–442.
  3. Shen C, Che G. Congenital eventration of hemidiaphragm in an adult. Ann Thorac Surg 2012; 94:e137–e139.
  4. Porpodis K, Zarogoulidis P, Spyratos D, et al. Pneumothorax and asthma. J Thorac Dis 2014; 6(suppl 1):S152–S161.
Issue
Cleveland Clinic Journal of Medicine - 83(1)
Issue
Cleveland Clinic Journal of Medicine - 83(1)
Page Number
19-20
Page Number
19-20
Publications
Publications
Topics
Article Type
Display Headline
Eventration of the diaphragm presenting as spontaneous pneumothorax
Display Headline
Eventration of the diaphragm presenting as spontaneous pneumothorax
Legacy Keywords
diaphragm, eventration, pneumothorax, hernia, Pauline Go, Zane Hammoud
Legacy Keywords
diaphragm, eventration, pneumothorax, hernia, Pauline Go, Zane Hammoud
Sections
Disallow All Ads
Alternative CME
Article PDF Media

Bony bumps in the mouth

Article Type
Changed
Display Headline
Bony bumps in the mouth

A 79-year-old woman with a long history of limited scleroderma was being evaluated in the rheumatology clinic. During routine examination of the oral cavity, masses were noted on her hard palate and on the lingual surface of both sides of the mandible (Figure 1). The masses had a bony consistency. The patient said that she had had these lumps for as long as she could remember, and that they were painless and had never caused any discomfort.

The masses were diagnosed as torus palatinus and torus mandibularis, localized benign overgrowths of cortical bone. The patient was reassured about the benign nature of these masses, and as they were asymptomatic, no further action was considered necessary.

TORUS PALATINUS AND TORUS MANDIBULARIS

Figure 1. Torus palatinus (left) is an exostosis arising from the median raphe of the palatine bone, whereas torus mandibularis (right) arises in the premolar area of the lingual surface of the mandible. These bony excrescences are benign, are usually asymptomatic, and require no treatment.

Torus palatinus and torus mandibularis are common exostoses of the mouth, ie, localized benign bony overgrowths arising from cortical bone.1 They are occasionally found incidentally during routine examination of the oral cavity. Patients should be reassured about the nonpathologic nature of this condition.

The condition is thought to be multifactorial, with causal factors including autosomal dominant inheritance, trauma, and lifestyle factors2 such as vitamin deficiency,3 a calcium-rich diet,3 fish consumption,4,5 and chewing on dry, raw, or frozen meat (as in Eskimo cultures).3 Masticatory hyperfunction and bruxism are thought to be risk factors.2,3

Epidemiologic studies indicate that oral tori are more common in women, and the prevalence varies considerably between geographic areas and ethnic groups.3 It is more common in Native Americans, Eskimos, Norwegians, and Thais.4

Torus palatinus is the most prevalent oral torus, occurring in 20% of the US population.6 It arises from the median raphe of the palatine bone and can vary in shape and size. Torus mandibularis is a protuberance arising in the premolar area of the lingual surface of the mandible.3 This form is much less common than torus palatinus, with a prevalence of 6%, and is bilateral in about 80% of cases.

Microscopic examination of tori reveal a mass of dense, lamellar, cortical bone with a small amount of fibrofatty marrow.1 An inner zone of trabecular bone may also be present.1

DIFFERENTIAL DIAGNOSIS

Oral tori must be differentiated from other growths in the mouth including fibromas, mucoceles, osteomas, osteochondromas, and osteoid osteomas.4 However, oral tori can usually be distinguished from other conditions on the basis of clinical findings alone. Biopsy may be warranted if there is doubt.4

Tori tend to grow gradually throughout life and do not have potential for malignant transformation.4 Although they are typically asymptomatic, removal is sometimes warranted for proper fitting of prostheses or for use in autogenous cortical bone grafting.5

References
  1. Neville BW, Douglas DD, Carl MA, Bouquot J. Developmental defects of the oral and maxillofacial region. In: Neville BW, Douglas DD, Carl MA, Bouquot J, eds. Oral and Maxillofacial Pathology. 3rd ed. St. Louis, MO: WB Saunders; 2009:1–53.
  2. Eggen S. Torus mandibularis: an estimation of the degree of genetic determination. Acta Odontol Scand 1989; 47:409–415.
  3. Loukas M, Hulsberg P, Tubbs RS, et al. The tori of the mouth and ear: a review. Clin Anat 2013; 26:953–960.
  4. Ladizinski B, Lee KC. A nodular protuberance on the hard palate. JAMA 2014; 311:1558–1559.
  5. García-García AS, Martínez-González JM, Gómez-Font R, Soto-Rivadeneira A, Oviedo-Roldán L. Current status of the torus palatinus and torus mandibularis. Med Oral Patol Oral Cir Bucal 2010; 15:e353–e360.
  6. Larheim TA, Westesson PL. Facial growth disturbances. In: Maxillofacial Imaging. Berlin/Heidelberg: Springer-Verlag, 2008:231.
Article PDF
Author and Disclosure Information

Soumya Chatterjee, MD, MS, FRCP
Associate Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, and Staff, Department of Rheumatologic and Immunologic Diseases, Orthopaedic and Rheumatologic Institute, Cleveland Clinic

Address: Soumya Chatterjee, MD, MS, FRCP, Department of Rheumatologic and Immunologic Diseases, A50, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: chattes@ccf.org

Issue
Cleveland Clinic Journal of Medicine - 83(1)
Publications
Topics
Page Number
17-18
Legacy Keywords
bony bumps, torus palatinus, exostosis, torus mandibularis, benign tumor, Soumya Chatterjee
Sections
Author and Disclosure Information

Soumya Chatterjee, MD, MS, FRCP
Associate Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, and Staff, Department of Rheumatologic and Immunologic Diseases, Orthopaedic and Rheumatologic Institute, Cleveland Clinic

Address: Soumya Chatterjee, MD, MS, FRCP, Department of Rheumatologic and Immunologic Diseases, A50, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: chattes@ccf.org

Author and Disclosure Information

Soumya Chatterjee, MD, MS, FRCP
Associate Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, and Staff, Department of Rheumatologic and Immunologic Diseases, Orthopaedic and Rheumatologic Institute, Cleveland Clinic

Address: Soumya Chatterjee, MD, MS, FRCP, Department of Rheumatologic and Immunologic Diseases, A50, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: chattes@ccf.org

Article PDF
Article PDF
Related Articles

A 79-year-old woman with a long history of limited scleroderma was being evaluated in the rheumatology clinic. During routine examination of the oral cavity, masses were noted on her hard palate and on the lingual surface of both sides of the mandible (Figure 1). The masses had a bony consistency. The patient said that she had had these lumps for as long as she could remember, and that they were painless and had never caused any discomfort.

The masses were diagnosed as torus palatinus and torus mandibularis, localized benign overgrowths of cortical bone. The patient was reassured about the benign nature of these masses, and as they were asymptomatic, no further action was considered necessary.

TORUS PALATINUS AND TORUS MANDIBULARIS

Figure 1. Torus palatinus (left) is an exostosis arising from the median raphe of the palatine bone, whereas torus mandibularis (right) arises in the premolar area of the lingual surface of the mandible. These bony excrescences are benign, are usually asymptomatic, and require no treatment.

Torus palatinus and torus mandibularis are common exostoses of the mouth, ie, localized benign bony overgrowths arising from cortical bone.1 They are occasionally found incidentally during routine examination of the oral cavity. Patients should be reassured about the nonpathologic nature of this condition.

The condition is thought to be multifactorial, with causal factors including autosomal dominant inheritance, trauma, and lifestyle factors2 such as vitamin deficiency,3 a calcium-rich diet,3 fish consumption,4,5 and chewing on dry, raw, or frozen meat (as in Eskimo cultures).3 Masticatory hyperfunction and bruxism are thought to be risk factors.2,3

Epidemiologic studies indicate that oral tori are more common in women, and the prevalence varies considerably between geographic areas and ethnic groups.3 It is more common in Native Americans, Eskimos, Norwegians, and Thais.4

Torus palatinus is the most prevalent oral torus, occurring in 20% of the US population.6 It arises from the median raphe of the palatine bone and can vary in shape and size. Torus mandibularis is a protuberance arising in the premolar area of the lingual surface of the mandible.3 This form is much less common than torus palatinus, with a prevalence of 6%, and is bilateral in about 80% of cases.

Microscopic examination of tori reveal a mass of dense, lamellar, cortical bone with a small amount of fibrofatty marrow.1 An inner zone of trabecular bone may also be present.1

DIFFERENTIAL DIAGNOSIS

Oral tori must be differentiated from other growths in the mouth including fibromas, mucoceles, osteomas, osteochondromas, and osteoid osteomas.4 However, oral tori can usually be distinguished from other conditions on the basis of clinical findings alone. Biopsy may be warranted if there is doubt.4

Tori tend to grow gradually throughout life and do not have potential for malignant transformation.4 Although they are typically asymptomatic, removal is sometimes warranted for proper fitting of prostheses or for use in autogenous cortical bone grafting.5

A 79-year-old woman with a long history of limited scleroderma was being evaluated in the rheumatology clinic. During routine examination of the oral cavity, masses were noted on her hard palate and on the lingual surface of both sides of the mandible (Figure 1). The masses had a bony consistency. The patient said that she had had these lumps for as long as she could remember, and that they were painless and had never caused any discomfort.

The masses were diagnosed as torus palatinus and torus mandibularis, localized benign overgrowths of cortical bone. The patient was reassured about the benign nature of these masses, and as they were asymptomatic, no further action was considered necessary.

TORUS PALATINUS AND TORUS MANDIBULARIS

Figure 1. Torus palatinus (left) is an exostosis arising from the median raphe of the palatine bone, whereas torus mandibularis (right) arises in the premolar area of the lingual surface of the mandible. These bony excrescences are benign, are usually asymptomatic, and require no treatment.

Torus palatinus and torus mandibularis are common exostoses of the mouth, ie, localized benign bony overgrowths arising from cortical bone.1 They are occasionally found incidentally during routine examination of the oral cavity. Patients should be reassured about the nonpathologic nature of this condition.

The condition is thought to be multifactorial, with causal factors including autosomal dominant inheritance, trauma, and lifestyle factors2 such as vitamin deficiency,3 a calcium-rich diet,3 fish consumption,4,5 and chewing on dry, raw, or frozen meat (as in Eskimo cultures).3 Masticatory hyperfunction and bruxism are thought to be risk factors.2,3

Epidemiologic studies indicate that oral tori are more common in women, and the prevalence varies considerably between geographic areas and ethnic groups.3 It is more common in Native Americans, Eskimos, Norwegians, and Thais.4

Torus palatinus is the most prevalent oral torus, occurring in 20% of the US population.6 It arises from the median raphe of the palatine bone and can vary in shape and size. Torus mandibularis is a protuberance arising in the premolar area of the lingual surface of the mandible.3 This form is much less common than torus palatinus, with a prevalence of 6%, and is bilateral in about 80% of cases.

Microscopic examination of tori reveal a mass of dense, lamellar, cortical bone with a small amount of fibrofatty marrow.1 An inner zone of trabecular bone may also be present.1

DIFFERENTIAL DIAGNOSIS

Oral tori must be differentiated from other growths in the mouth including fibromas, mucoceles, osteomas, osteochondromas, and osteoid osteomas.4 However, oral tori can usually be distinguished from other conditions on the basis of clinical findings alone. Biopsy may be warranted if there is doubt.4

Tori tend to grow gradually throughout life and do not have potential for malignant transformation.4 Although they are typically asymptomatic, removal is sometimes warranted for proper fitting of prostheses or for use in autogenous cortical bone grafting.5

References
  1. Neville BW, Douglas DD, Carl MA, Bouquot J. Developmental defects of the oral and maxillofacial region. In: Neville BW, Douglas DD, Carl MA, Bouquot J, eds. Oral and Maxillofacial Pathology. 3rd ed. St. Louis, MO: WB Saunders; 2009:1–53.
  2. Eggen S. Torus mandibularis: an estimation of the degree of genetic determination. Acta Odontol Scand 1989; 47:409–415.
  3. Loukas M, Hulsberg P, Tubbs RS, et al. The tori of the mouth and ear: a review. Clin Anat 2013; 26:953–960.
  4. Ladizinski B, Lee KC. A nodular protuberance on the hard palate. JAMA 2014; 311:1558–1559.
  5. García-García AS, Martínez-González JM, Gómez-Font R, Soto-Rivadeneira A, Oviedo-Roldán L. Current status of the torus palatinus and torus mandibularis. Med Oral Patol Oral Cir Bucal 2010; 15:e353–e360.
  6. Larheim TA, Westesson PL. Facial growth disturbances. In: Maxillofacial Imaging. Berlin/Heidelberg: Springer-Verlag, 2008:231.
References
  1. Neville BW, Douglas DD, Carl MA, Bouquot J. Developmental defects of the oral and maxillofacial region. In: Neville BW, Douglas DD, Carl MA, Bouquot J, eds. Oral and Maxillofacial Pathology. 3rd ed. St. Louis, MO: WB Saunders; 2009:1–53.
  2. Eggen S. Torus mandibularis: an estimation of the degree of genetic determination. Acta Odontol Scand 1989; 47:409–415.
  3. Loukas M, Hulsberg P, Tubbs RS, et al. The tori of the mouth and ear: a review. Clin Anat 2013; 26:953–960.
  4. Ladizinski B, Lee KC. A nodular protuberance on the hard palate. JAMA 2014; 311:1558–1559.
  5. García-García AS, Martínez-González JM, Gómez-Font R, Soto-Rivadeneira A, Oviedo-Roldán L. Current status of the torus palatinus and torus mandibularis. Med Oral Patol Oral Cir Bucal 2010; 15:e353–e360.
  6. Larheim TA, Westesson PL. Facial growth disturbances. In: Maxillofacial Imaging. Berlin/Heidelberg: Springer-Verlag, 2008:231.
Issue
Cleveland Clinic Journal of Medicine - 83(1)
Issue
Cleveland Clinic Journal of Medicine - 83(1)
Page Number
17-18
Page Number
17-18
Publications
Publications
Topics
Article Type
Display Headline
Bony bumps in the mouth
Display Headline
Bony bumps in the mouth
Legacy Keywords
bony bumps, torus palatinus, exostosis, torus mandibularis, benign tumor, Soumya Chatterjee
Legacy Keywords
bony bumps, torus palatinus, exostosis, torus mandibularis, benign tumor, Soumya Chatterjee
Sections
Disallow All Ads
Alternative CME
Article PDF Media

Vitamin B12 deficiency

Article Type
Changed
Display Headline
Vitamin B12 deficiency

To the Editor: In the article “An unusual cause of vitamin B12 and iron deficiency,”1 the diagnosis of vitamin B12 deficiency was made only by a vitamin B12 level of 108 pg/mL.

According to Harrison’s Principles of Internal Medicine, 18th edition, page 870, the diagnosis of vitamin B12 deficiency requires measurement of methylmalonic acid. Either this test was not performed on the 76-year-old woman described in the article, or the result was not entered. Without a methylmalonic acid level, the title of this article seems incorrect, or the article itself is incomplete by not including this level. The correct diagnosis of anemia due to an intestinal tapeworm was made by capsule endoscopy. She received appropriate therapy and her anemia cleared quickly.

If there is an updated concept for diagnosing vitamin B12 deficiency, I’m open to learning about it.

References
  1. Maithel S, Duong AK, Zhang J, Nguyen DL. An unusual cause of vitamin B12 and iron deficiency. Cleve Clin J Med 2015; 82:406–408.
Article PDF
Author and Disclosure Information

Kenneth R. Phillips, MS, MD, FCCP
Apponaug Diagnostics and Therapeutics, Warwick, RI

Issue
Cleveland Clinic Journal of Medicine - 83(1)
Publications
Topics
Page Number
15
Legacy Keywords
Vitamin B12, tapeworm, Kenneth Phillips
Sections
Author and Disclosure Information

Kenneth R. Phillips, MS, MD, FCCP
Apponaug Diagnostics and Therapeutics, Warwick, RI

Author and Disclosure Information

Kenneth R. Phillips, MS, MD, FCCP
Apponaug Diagnostics and Therapeutics, Warwick, RI

Article PDF
Article PDF
Related Articles

To the Editor: In the article “An unusual cause of vitamin B12 and iron deficiency,”1 the diagnosis of vitamin B12 deficiency was made only by a vitamin B12 level of 108 pg/mL.

According to Harrison’s Principles of Internal Medicine, 18th edition, page 870, the diagnosis of vitamin B12 deficiency requires measurement of methylmalonic acid. Either this test was not performed on the 76-year-old woman described in the article, or the result was not entered. Without a methylmalonic acid level, the title of this article seems incorrect, or the article itself is incomplete by not including this level. The correct diagnosis of anemia due to an intestinal tapeworm was made by capsule endoscopy. She received appropriate therapy and her anemia cleared quickly.

If there is an updated concept for diagnosing vitamin B12 deficiency, I’m open to learning about it.

To the Editor: In the article “An unusual cause of vitamin B12 and iron deficiency,”1 the diagnosis of vitamin B12 deficiency was made only by a vitamin B12 level of 108 pg/mL.

According to Harrison’s Principles of Internal Medicine, 18th edition, page 870, the diagnosis of vitamin B12 deficiency requires measurement of methylmalonic acid. Either this test was not performed on the 76-year-old woman described in the article, or the result was not entered. Without a methylmalonic acid level, the title of this article seems incorrect, or the article itself is incomplete by not including this level. The correct diagnosis of anemia due to an intestinal tapeworm was made by capsule endoscopy. She received appropriate therapy and her anemia cleared quickly.

If there is an updated concept for diagnosing vitamin B12 deficiency, I’m open to learning about it.

References
  1. Maithel S, Duong AK, Zhang J, Nguyen DL. An unusual cause of vitamin B12 and iron deficiency. Cleve Clin J Med 2015; 82:406–408.
References
  1. Maithel S, Duong AK, Zhang J, Nguyen DL. An unusual cause of vitamin B12 and iron deficiency. Cleve Clin J Med 2015; 82:406–408.
Issue
Cleveland Clinic Journal of Medicine - 83(1)
Issue
Cleveland Clinic Journal of Medicine - 83(1)
Page Number
15
Page Number
15
Publications
Publications
Topics
Article Type
Display Headline
Vitamin B12 deficiency
Display Headline
Vitamin B12 deficiency
Legacy Keywords
Vitamin B12, tapeworm, Kenneth Phillips
Legacy Keywords
Vitamin B12, tapeworm, Kenneth Phillips
Sections
Disallow All Ads
Alternative CME
Article PDF Media

In reply: Vitamin B12 deficiency

Article Type
Changed
Display Headline
In reply: Vitamin B12 deficiency

In Reply: We thank Dr. Phillips for his inquiry.

In general, serum vitamin B12 concentrations vary greatly, and we acknowledge that serum vitamin B12 may be normal in up to 5% of patients with documented B12 deficiency.1 In a prospective study of 1,599 patients, Matchar et al2 demonstrated that a single vitamin B12 level less than 200 pg/mL had a specificity greater than 95% at predicting vitamin B12 deficiency.2 We acknowledge that additional metabolite testing is necessary in equivocal cases in which the vitamin B12 level is between 200 and 300 pg/mL, which is often considered to be the normal range, but the patient has symptoms of vitamin B12 deficiency such as dementia and unexplained macrocytosis, and neurologic symptoms.3

Based on the patient’s symptoms of neuropathy and fatigue in conjunction with a vitamin B12 level well below 200 pg/mL, we believe that the diagnosis can be made.2,3 Nonetheless, although we did not mention it in our article, we did indeed send for a methylmalonic acid measurement at the time of the initial evaluation, and the level was elevated at 396 nmol/L (normal 87–318 nmol/L), further confirming her vitamin B12 deficiency.

References
  1. Naurath HJ, Joosten E, Riezler R, Stabler SP, Allen RH, Lindenbaum J. Effects of vitamin B12, folate, and vitamin B6 supplements in elderly people with normal serum vitamin concentrations. Lancet 1995; 346:85–89.
  2. Matchar DB, McCrory DC, Millington DS, Feussner JR. Performance of the serum cobalamin assay for diagnosis of cobalamin deficiency. Am J Med Sci 1994; 308:276–283.
  3. Stabler SP. Clinical practice. Vitamin B12 deficiency. N Eng J Med 2013; 368:149–160.
Article PDF
Author and Disclosure Information

Douglas L. Nguyen, MD
Assistant Clinical Professor of Medicine, University of California, Irvine

Shelly Maithel
University of California, Irvine

Alex K. Duong
University of California, Irvine

Jonathan Zhang, MD
University of California, Irvine

Issue
Cleveland Clinic Journal of Medicine - 83(1)
Publications
Topics
Page Number
15
Legacy Keywords
Vitamin B12, tapeworm, Douglas Nguyen, Shelly Maithel, Alex Duong, Jonathan Zhang
Sections
Author and Disclosure Information

Douglas L. Nguyen, MD
Assistant Clinical Professor of Medicine, University of California, Irvine

Shelly Maithel
University of California, Irvine

Alex K. Duong
University of California, Irvine

Jonathan Zhang, MD
University of California, Irvine

Author and Disclosure Information

Douglas L. Nguyen, MD
Assistant Clinical Professor of Medicine, University of California, Irvine

Shelly Maithel
University of California, Irvine

Alex K. Duong
University of California, Irvine

Jonathan Zhang, MD
University of California, Irvine

Article PDF
Article PDF
Related Articles

In Reply: We thank Dr. Phillips for his inquiry.

In general, serum vitamin B12 concentrations vary greatly, and we acknowledge that serum vitamin B12 may be normal in up to 5% of patients with documented B12 deficiency.1 In a prospective study of 1,599 patients, Matchar et al2 demonstrated that a single vitamin B12 level less than 200 pg/mL had a specificity greater than 95% at predicting vitamin B12 deficiency.2 We acknowledge that additional metabolite testing is necessary in equivocal cases in which the vitamin B12 level is between 200 and 300 pg/mL, which is often considered to be the normal range, but the patient has symptoms of vitamin B12 deficiency such as dementia and unexplained macrocytosis, and neurologic symptoms.3

Based on the patient’s symptoms of neuropathy and fatigue in conjunction with a vitamin B12 level well below 200 pg/mL, we believe that the diagnosis can be made.2,3 Nonetheless, although we did not mention it in our article, we did indeed send for a methylmalonic acid measurement at the time of the initial evaluation, and the level was elevated at 396 nmol/L (normal 87–318 nmol/L), further confirming her vitamin B12 deficiency.

In Reply: We thank Dr. Phillips for his inquiry.

In general, serum vitamin B12 concentrations vary greatly, and we acknowledge that serum vitamin B12 may be normal in up to 5% of patients with documented B12 deficiency.1 In a prospective study of 1,599 patients, Matchar et al2 demonstrated that a single vitamin B12 level less than 200 pg/mL had a specificity greater than 95% at predicting vitamin B12 deficiency.2 We acknowledge that additional metabolite testing is necessary in equivocal cases in which the vitamin B12 level is between 200 and 300 pg/mL, which is often considered to be the normal range, but the patient has symptoms of vitamin B12 deficiency such as dementia and unexplained macrocytosis, and neurologic symptoms.3

Based on the patient’s symptoms of neuropathy and fatigue in conjunction with a vitamin B12 level well below 200 pg/mL, we believe that the diagnosis can be made.2,3 Nonetheless, although we did not mention it in our article, we did indeed send for a methylmalonic acid measurement at the time of the initial evaluation, and the level was elevated at 396 nmol/L (normal 87–318 nmol/L), further confirming her vitamin B12 deficiency.

References
  1. Naurath HJ, Joosten E, Riezler R, Stabler SP, Allen RH, Lindenbaum J. Effects of vitamin B12, folate, and vitamin B6 supplements in elderly people with normal serum vitamin concentrations. Lancet 1995; 346:85–89.
  2. Matchar DB, McCrory DC, Millington DS, Feussner JR. Performance of the serum cobalamin assay for diagnosis of cobalamin deficiency. Am J Med Sci 1994; 308:276–283.
  3. Stabler SP. Clinical practice. Vitamin B12 deficiency. N Eng J Med 2013; 368:149–160.
References
  1. Naurath HJ, Joosten E, Riezler R, Stabler SP, Allen RH, Lindenbaum J. Effects of vitamin B12, folate, and vitamin B6 supplements in elderly people with normal serum vitamin concentrations. Lancet 1995; 346:85–89.
  2. Matchar DB, McCrory DC, Millington DS, Feussner JR. Performance of the serum cobalamin assay for diagnosis of cobalamin deficiency. Am J Med Sci 1994; 308:276–283.
  3. Stabler SP. Clinical practice. Vitamin B12 deficiency. N Eng J Med 2013; 368:149–160.
Issue
Cleveland Clinic Journal of Medicine - 83(1)
Issue
Cleveland Clinic Journal of Medicine - 83(1)
Page Number
15
Page Number
15
Publications
Publications
Topics
Article Type
Display Headline
In reply: Vitamin B12 deficiency
Display Headline
In reply: Vitamin B12 deficiency
Legacy Keywords
Vitamin B12, tapeworm, Douglas Nguyen, Shelly Maithel, Alex Duong, Jonathan Zhang
Legacy Keywords
Vitamin B12, tapeworm, Douglas Nguyen, Shelly Maithel, Alex Duong, Jonathan Zhang
Sections
Disallow All Ads
Alternative CME
Article PDF Media

Preoperative testing

Article Type
Changed
Display Headline
Preoperative testing

To the Editor: I read with great interest your 1-Minute Consult and the accompanying editorial on preoperative testing. I have long requested from my local hospitals the rationale for the long list of tests that used to be mandated for any surgery. I could not even get the courtesy of a reply from the department of anesthesia. For a while, in addition to the complete blood cell count and chemistry panel, one hospital demanded a urinalysis for cataract surgery.

Finally, without any explanation, the testing is now no longer mandated for cataract surgery but is still required for surgery such as the meniscus repair that was referenced.

These are not tests I want to order, but I am forced to order them or the surgery won’t be done. Certainly, in a diabetic patient or a patient treated with a complex regimen for hypertension, tests may be needed.

Thank you for the opportunity to comment.

Article PDF
Author and Disclosure Information

Cynthia Point, MD
San Francisco, CA

Issue
Cleveland Clinic Journal of Medicine - 83(1)
Publications
Topics
Page Number
16
Legacy Keywords
preoperative testing, Cynthia Point
Sections
Author and Disclosure Information

Cynthia Point, MD
San Francisco, CA

Author and Disclosure Information

Cynthia Point, MD
San Francisco, CA

Article PDF
Article PDF
Related Articles

To the Editor: I read with great interest your 1-Minute Consult and the accompanying editorial on preoperative testing. I have long requested from my local hospitals the rationale for the long list of tests that used to be mandated for any surgery. I could not even get the courtesy of a reply from the department of anesthesia. For a while, in addition to the complete blood cell count and chemistry panel, one hospital demanded a urinalysis for cataract surgery.

Finally, without any explanation, the testing is now no longer mandated for cataract surgery but is still required for surgery such as the meniscus repair that was referenced.

These are not tests I want to order, but I am forced to order them or the surgery won’t be done. Certainly, in a diabetic patient or a patient treated with a complex regimen for hypertension, tests may be needed.

Thank you for the opportunity to comment.

To the Editor: I read with great interest your 1-Minute Consult and the accompanying editorial on preoperative testing. I have long requested from my local hospitals the rationale for the long list of tests that used to be mandated for any surgery. I could not even get the courtesy of a reply from the department of anesthesia. For a while, in addition to the complete blood cell count and chemistry panel, one hospital demanded a urinalysis for cataract surgery.

Finally, without any explanation, the testing is now no longer mandated for cataract surgery but is still required for surgery such as the meniscus repair that was referenced.

These are not tests I want to order, but I am forced to order them or the surgery won’t be done. Certainly, in a diabetic patient or a patient treated with a complex regimen for hypertension, tests may be needed.

Thank you for the opportunity to comment.

Issue
Cleveland Clinic Journal of Medicine - 83(1)
Issue
Cleveland Clinic Journal of Medicine - 83(1)
Page Number
16
Page Number
16
Publications
Publications
Topics
Article Type
Display Headline
Preoperative testing
Display Headline
Preoperative testing
Legacy Keywords
preoperative testing, Cynthia Point
Legacy Keywords
preoperative testing, Cynthia Point
Sections
Disallow All Ads
Alternative CME
Article PDF Media

Targeting gut flora to treat and prevent disease

Article Type
Changed
Display Headline
Targeting gut flora to treat and prevent disease

PRACTICE RECOMMENDATIONS

› Encourage patients to eat a healthy diet that includes an adequate amount of soluble fiber to maintain a healthy, diverse microbiome. B
› Recommend combination probiotics to treat symptoms of irritable bowel syndrome. A
› Encourage patients to take probiotics containing Lactobacillus species to prevent antibiotic-associated diarrhea and Saccharomyces to prevent Clostridium difficile infection. A
› Recommend probiotics containing Lactobacillus species and/or Saccharomyces to treat acute infectious diarrhea. A

Strength of recommendation (SOR)

A Good-quality patient-oriented evidence
B Inconsistent or limited-quality patient-oriented evidence
C
Consensus, usual practice, opinion, disease-oriented evidence, case series

CASE 1 Sheila S, age 27, has irritable bowel syndrome (IBS) and comes to your office for a follow-up visit. Over the past 6 months she has started taking a fiber supplement, drinking more water, and looking for links between stress and her symptoms. She has read about probiotics and wonders if you would consider recommending them in her situation.

CASE 2 Mark M, age 45, has type 2 diabetes and is overweight. He is motivated to change his diet and has started to exercise more. He is taking metformin 2000 mg/d but his hemoglobin A1c remains slightly elevated at 7.2%. He heard on television that probiotics might help to keep him from needing to add another medication.

Most of the living organisms that comprise the human microbiome—all of the microbes that live on or in humans—are found in the gastrointestinal (GI) tract. The gut flora contribute 99% of the genetic material in the human body. The composition of the gut flora is remarkably diverse across the population; each individual has a unique microbial footprint. Within this microbial diversity, there appears to be a stable number of genes that are responsible for the major functions of the gut flora.1 These microbes:

  • supply essential nutrients by breaking down complex carbohydrates;
  • generate secondary bile acids that assist in digesting fats;2
  • synthesize vitamins such as K, B12, folate, and biotin;3
  • contribute to the defensive barrier in the colon by keeping pathogenic bacteria from crossing the colonic mucosa; and
  • interact with our systemic immune system in a way that maintains a level of homeostasis, allowing for appropriate activation in the face of pathogens without developing autoimmunity.4

The gut flora also play a role in the communication between the central nervous system and the enteric nervous system by modulating the hormonal and neural pathways that have been labeled the “gut-brain axis.” The gut-brain axis has been associated with numerous disease states, including irritable bowel syndrome and certain psychiatric disorders.5

Researchers are investigating interventions that target the microbiome to increase microbial diversity and the presence of certain species to prevent or treat various diseases. The use of probiotics and dietary changes to increase intake of soluble fiber have been the most studied of these interventions. The thought is that these interventions can correct an imbalance, or dysbiosis, of the gut flora.6 Studies have shown that decreased microbial diversity is associated with elevations of certain disease markers (eg, adiposity, insulin, triglycerides, C–reactive protein)7 and that increases in soluble fiber lead to the greatest long-term improvement in microbial diversity.8 Fecal transplant—the transfer of a processed mixture of stool that contains “healthy” bacteria from a donor into the intestines of a patient—is being explored as a method of replacing colonic gut flora, but evidence is limited.

The following review takes a closer look at these options and identifies those that are most likely to benefit patients in the treatment—and prevention—of several diseases (TABLE 1).9-16

Evidence is best for using probiotics for digestive diseases

Dietary interventions for digestive diseases have long been studied, but are getting renewed attention for their potential impact on the microbiome.17 Beyond dietary modification, other similar treatment options include probiotics (live microorganisms thought to confer a beneficial effect on the host), prebiotics (non-digestible food ingredients, including oligosaccharides and inulin, thought to promote the growth of “helpful” gut flora), and synbiotics (combinations of the 2).18

Irritable bowel syndrome (IBS) is a heterogeneous disorder characterized by altered intestinal transit, low-grade colonic inflammation, and/or alterations in the gutbrain axis. Research has increasingly focused on recently discovered increases in intestinal immune activation, intestinal permeability, and alterations in the colonic microbiome (decreased diversity and increased pathogenic bacteria) associated with IBS.19

Meta-analyses have found that combination probiotics benefit patients with ulcerative colitis, but not those with Crohn’s disease.

A meta-analysis of 43 randomized control trials (RCTs) found probiotics ranging from Lactobacillus to Saccharomyces can significantly decrease global IBS symptoms, abdominal pain, bloating, and flatulence.9 For a patient such as Ms. S, the evidence suggests a probiotic that contains a mixture of Lactobacillus and Bifidobacterium might help relieve her symptoms.9 In terms of dietary modifications, soluble fiber, which is already known to help treat IBS,20 has profound effects on improving microbiota diversity and in shifting the composition toward less pathogenic strains.21 The Institute of Medicine's daily recommended intake of soluble fiber is about 15 g/d.22

Inflammatory bowel disease (IBD) is caused by inflammation of the GI lining due to an overactive immune response. Evidence shows that patients with IBD have an altered microbial composition—specifically, an increase in bacteria that produce pro-inflammatory molecules and a decrease in bacteria that have a dampening effect on immune activation.23

Most studies evaluating probiotics as a treatment for IBD have been small and have used a wide variety of bacterial mixtures, which makes comparisons difficult. Recent meta-analyses found combination probiotics can both induce and maintain remission in patients with ulcerative colitis, but have no beneficial effects in Crohn’s disease.10 In a review of 9 case series of patients with IBD, fecal transplant reduced IBD symptoms, and patients were able to decrease medication use.24

Diarrheal illness. The human intestine is protected from diarrheal illness by healthy bacteria that block the actions of pathogenic bacteria. This mechanism is called colonization resistance. Moderate levels of evidence support the use of probiotics to prevent or treat several types of diarrheal illness.14

Antibiotic-associated diarrhea (AAD) is caused when antibiotic use alters the microbial balance. Recent meta-analyses have shown probiotics can prevent AAD and Clostridium difficile-associated diarrhea.11,12 Several case series and one RCT have found that fecal transplants are safe and efficacious for treating recurrent Clostridium difficile infection.25 Using probiotics to treat symptoms of AAD has been less studied.

Acute infectious diarrhea and traveler’s diarrhea (TD). A Cochrane review found that probiotics decreased the duration of diarrheal episodes by 25 hours, decreased the risk of an episode lasting more than 4 days by 59%, and led to one less diarrheal stool per day by the second day of the intervention.13 In a separate meta-analysis of 12 studies, probiotics significantly prevented 85% of cases of TD.14

Encouraging early evidence for several other illnesses

Metabolic disorders. Both animal and human studies support the theory that gut flora contribute to energy homeostasis, and in some genetically predisposed people dysbiosis may lead to obesity and diabetes. The traditional western diet4 and possibly decreased physical activity26 are major contributors to gut flora dysbiosis. Healthy bacteria in the gut break down soluble fiber into short chain fatty acids (SCFAs). SCFAs are associated with increased satiety, decreased food intake, lower levels of inflammation, and improvement in insulin signaling in adipose tissue. In addition to decreased SFCA production, dysbiosis also leads to increased lipid deposition through higher levels of lipoprotein lipase.27

Obesity. The bacteria in our gut affect energy metabolism. In patients with obesity, increased amounts of bacteria in the taxa Firmicutes and a corresponding decrease in Bacteroidetes is associated with an increased energy harvest and decreased SCFA production, which leads to a pro-inflammatory state.28 Probiotics that contain Bifidobacterium and Lactobacillus are thought to help correct this dysbiosis by increasing production of SCFAs.28

A recent meta-analysis of 4 RCTs found no significant difference between supplementation with probiotics and placebo on weight reduction.29 However, lower-quality studies with more subjects and longer duration have shown a statistically significant improvement in weight reduction with probiotic use compared to placebo.29

The evidence suggests that fecal transplants are safe and efficacious for treating recurrent Clostridium difficile infection.

Diabetes. Although dietary interventions to improve glycemic control have long been an important cornerstone of treatment, probiotic supplementation to further alter gut flora composition is also being evaluated. Studies have found probiotics have largely beneficial effects on glycemic control, especially in animals. The largest systematic review to date looked at 33 studies, including 5 human trials. The human studies each found a significant reduction in at least one of 6 parameters of glycemic control (levels of fasting plasma glucose, postprandial blood glucose, glycated hemoglobin, insulin, insulin resistance, and onset of diabetes).16 It is unclear which probiotic strains confer benefit, and if those benefits are sustainable without dietary modification and increased physical activity.

Psychiatric illnesses. The gut-brain axis is thought to impact mental health by several mechanisms, including modulating the hypothalamic-pituitary-adrenal axis, activating the immune system, producing active metabolites, and affecting the vagus nerve. It is unclear which of these pathways may be clinically relevant.5,30 The few human studies that have looked for a potential link between gut flora and psychiatric illness have focused on depression and autism spectrum disorders (ASD).

Depression. Small studies comparing the microbiome composition of depressed patients vs healthy controls have found differences in patterns of both over- and underrepresented microbiota species in depressed patients, although the patterns across studies have been inconsistent.31,32 One small functional magnetic resonance imaging study of healthy women showed that a fermented milk product that contained probiotics affected activity in areas of the brain that control emotion and sensation.33 A few small studies have shown that patients who used probiotics had improved depression scores.34 Further studies are needed.

ASD. Children with ASD have GI disturbances—most commonly diarrhea, constipation, and/or bloating—more often than healthy controls.35,36 This association has led to speculation of a connection between the gut and brain. The microbial composition and diversity appears to be different in individuals with ASD; several studies have found an increase in Clostridia species.37

Research on probiotics for treating ASD has been primarily in preclinical models. Human studies of probiotics for ASD are lacking.38 Small studies on dietary modifications such as gluten-free and casein-free diets have had varying results; to what extent these dietary changes exert their influence via the intestinal microbiome is unknown.38

Eczema. Several studies have looked at the role of prebiotics and probiotics in reducing the risk for allergic disease. A 2013 Cochrane review found strong evidence that certain prebiotics can prevent eczema in children under age 2.15 There is limited evidence that probiotics may also play a role in preventing eczema.39,40 However, probiotics do not appear to be effective for treating eczema.41

Several studies have found a link between the use of probiotics and significant reductions in at least one of 6 parameters of glycemic control.

Rheumatoid arthritis (RA). Patients with RA have a change in the balance of function of different T helper cells subsets, and several studies have shown that changes in the gut microbiome can affect this balance.42 A recent small study of patients with RA found that 75% of those with new onset RA had Prevotella copri bacteria as the predominant species, and patients with chronic RA had a decrease in Bacteroides species compared to healthy counterparts.42-44 The exact influence of gut flora dysbiosis on RA is unknown.45 Small studies suggest dietary changes may improve RA symptoms, while data on the use of probiotics to alleviate symptoms is mixed.46

 

 

What to tell patients about gut flora and health

There is increasing evidence that the gut microbiome and the genes contained therein have an impact on an individual’s health. (See TABLE 2 for additional resources.) The best preventive advice for patients and their families is to eat a diet rich in fruits and vegetables. This measure has well proven benefits beyond its potential effects on gut flora.

Correcting dysbiosis with diet or probiotics may play a role in treating chronic conditions; however, in many cases, further research is required to elucidate specific recommendations. In the meantime, given the safety profile of probiotics and dietary fiber, it is reasonable to consider using these interventions, particularly probiotics for treating IBS, ulcerative colitis, and acute infectious diarrhea; probiotics for preventing antibiotic-associated diarrhea and traveler’s diarrhea; and prebiotics for preventing eczema in high-risk infants.

CORRESPONDENCE
Jill Schneiderhan, MD, Family Medicine at Domino’s Farms, 24 Frank Lloyd Wright Dr., Lobby H, Suite 2300, Ann Arbor, MI 48105; jillsch@umich.edu.

References

1. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486(7402):207-214.

2. Conlon MA, Bird AR. The impact of diet and lifestyle on gut microbiota and human health. Nutrients. 2015;7:17-44.

3. Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions. Science. 2012;336:1262-1267.

4. Zhang YJ, Li S, Gan RY, et al. Impacts of gut bacteria on human health and diseases. Int J Mol Sci. 2015;16:7493-7519.

5. Tillisch K. The effects of gut microbiota on CNS function in humans. Gut Microbes. 2014;5:404-410.

6. Belizario JE, Napolitano M. Human microbiomes and their roles in dysbiosis, common diseases, and novel therapeutic approaches. Front Microbiol. 2015;6:1050.

7. Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500:541-546.

8. Cotillard A, Kennedy SP, Kong LC, et al. Dietary intervention impact on gut microbial gene richness. Nature. 2013;500:585-588.

9. Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014;109:1547-1561; quiz 1546,1562.

10. Fujiya M, Ueno N, Kohgo Y. Probiotic treatments for induction and maintenance of remission in inflammatory bowel diseases: a meta-analysis of randomized controlled trials. Clin J Gastroenterol. 2014;7(1):1-13.

11. Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307:1959-1969.

12. Szajewska H, Kolodziej M. Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2015;42:793–801.

13. Allen SJ, Martinez EG, Gregorio GV, et al. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 2010(11):CD003048.

14. McFarland LV. Meta-analysis of probiotics for the prevention of traveler’s diarrhea. Travel Med Infect Dis. 2007;5:97-105.

15. Osborn DA, Sinn JK. Prebiotics in infants for prevention of allergy. The Cochrane Library. 2013. Cochrane Database Syst Rev. 2013;3:CD006474.

16. Razmpoosh E, Javadi M, Ejtahed HS, et al. Probiotics as beneficial agents in the management of diabetes mellitus: a systematic review. Diabetes Metab Res Rev. 2015. [Epub ahead of print].

17. Aguirre M, Eck A, Savelkoul PH, et al. Diet drives quick changes in the metabolic activity and composition of human gut microbiota in a validated in vitro gut model. Res Microbiol. 2015. [Epub ahead of print].

18. Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology. 2009;136:65-80.

19. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015;313:949-958.

20. Moayyedi P, Quigley EM, Lacy BE, et al. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109:1367-1374.

21. Simpson HL, Campbell BJ. Review article: dietary fibre-microbiota interactions. Aliment Pharmacol Ther. 2015;42:158-179.

22. Otten JJ, Hellwig JP, Meyers LD; Institute of Medicine of the National Academies. Dietary Reference Intakes: The essential guide to nutrient requirements. 2006. US Department of Agriculture Web site. Available at: http://www.nal.usda.gov/fnic/DRI/Essential_Guide/DRIEssentialGuideNutReq.pdf. Accessed December 8, 2015.

23. Hansen JJ, Sartor RB. Therapeutic manipulation of the microbiome in IBD: current results and future approaches. Curr Treat Options Gastroenterol. 2015;13:105-120.

24. Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther. 2012;36:503-516.

25. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol. 2014;48:693-702.

26. Bermon S, Petriz B, Kajeniene A, et al. The microbiota: an exercise immunology perspective. Exerc Immunol Rev. 2015;21:70-79.

27. Hur KY, Lee MS. Gut microbiota and metabolic disorders. Diabetes Metab J. 2015;39:198-203.

28. Devaraj S, Hemarajata P, Versalovic J. The human gut microbiome and body metabolism: implications for obesity and diabetes. Clin Chem. 2013;59:617-628.

29. Park S, Bae JH. Probiotics for weight loss: a systematic review and meta-analysis. Nutr Res. 2015;35:566-575.

30. Petra AI, Panagiotidou S, Hatziagelaki E, et al. Gut-microbiotabrain axis and its effect on neuropsychiatric disorders with suspected immune dysregulation. Clin Ther. 2015;37:984-995.

31. Jiang H, Ling Z, Zhang Y, et al. Altered fecal microbiota composition in patients with major depressive disorder. Brain Behav Immun. 2015;48:186-194.

32. Naseribafrouei A, Hestad K, Avershina E, et al. Correlation between the human fecal microbiota and depression. Neurogastroenterol Motil. 2014;26:1155-1162.

33. Tillisch K, Labus J, Kilpatrick L, et al. Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology. 2013;144:1394-1401.

34. Bested AC, Logan AC, Selhub EM. Intestinal microbiota, probiotics and mental health: from Metchnikoff to modern advances: part III - convergence toward clinical trials. Gut Pathog. 2013;5:4.

35. Krajmalnik-Brown R, Lozupone C, Kang DW, et al. Gut bacteria in children with autism spectrum disorders: challenges and promise of studying how a complex community influences a complex disease. Microb Ecol Health Dis. 2015;26:26914.

36. Buie T. Potential etiologic factors of microbiome disruption in autism. Clin Ther. 2015;37:976-983.

37. Cao X, Lin P, Jiang P, et al. Characteristics of the gastrointestinal microbiome in children with autism spectrum disorder: a systematic review. Shanghai Arch Psychiatry. 2013;25:342-353.

38. Frye RE, Slattery J, MacFabe DF, et al. Approaches to studying and manipulating the enteric microbiome to improve autism symptoms. Microb Ecol Health Dis. 2015;26:26878.

39. Osborn DA, Sinn JK. Probiotics in infants for prevention of allergic disease and food hypersensitivity. Cochrane Database Syst Rev. 2007;(4):CD006475.

40. Tang ML, Lahtinen SJ, Boyle RJ. Probiotics and prebiotics: clinical effects in allergic disease. Curr Opin Pediatr. 2010;22:626-634.

41. Boyle RJ, Bath-Hextall FJ, Leonardi-Bee J, et al. Probiotics for treating eczema. Cochrane Database Syst Rev. 2008;(4):CD006135.

42. Rogier R, Koenders MI, Abdollahi-Roodsaz S. Toll-like receptor mediated modulation of T cell response by commensal intestinal microbiota as a trigger for autoimmune arthritis. J Immunol Res. 2015;2015:527696.

43. Perez-Santiago Ja, Gianella Sa, Massanella Ma, et al. Gut Lactobacillales are associated with higher CD4 and less microbial translocation during HIV infection. AIDS. 2013;27:1921-1931.

44. Scher JU, Sczesnak A, Longman RS, et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife. 2013;2:e01202.

45. Scofield RH. Rheumatic diseases and the microbiome. Int J Rheum Dis. 2014;17:489-492.

46. Sandhya P, Danda D, Sharma D, et al. Does the buck stop with the bugs?: an overview of microbial dysbiosis in rheumatoid arthritis. Int J Rheum Dis. 2015. [Epub ahead of print].

Article PDF
Author and Disclosure Information

Jill Schneiderhan, MD
Tara Master-Hunter, MD
Amy Locke, MD, FAAFP

Department of Family Medicine, University of Michigan, Ann Arbor (Drs. Schneiderhan and Master-Hunter); Department of Family and Preventive Medicine, University of Utah, Salt Lake City (Dr. Locke)

jillsch@umich.edu

The authors reported no potential conflict of interest relevant to this article.

Issue
The Journal of Family Practice - 65(1)
Publications
Topics
Page Number
34-38
Legacy Keywords
Jill Schneiderhan, MD, Tara Master-Hunter, MD, Amy Locke, MD, FAAFP, gut flora, probiotics, prebiotics, nutrition, high-fiber diet, Clostridium difficile infection, irritable bowel syndrome, IBS, Saccharomyces, gastrointestinal tract, gastrointestinal, GI
Sections
Author and Disclosure Information

Jill Schneiderhan, MD
Tara Master-Hunter, MD
Amy Locke, MD, FAAFP

Department of Family Medicine, University of Michigan, Ann Arbor (Drs. Schneiderhan and Master-Hunter); Department of Family and Preventive Medicine, University of Utah, Salt Lake City (Dr. Locke)

jillsch@umich.edu

The authors reported no potential conflict of interest relevant to this article.

Author and Disclosure Information

Jill Schneiderhan, MD
Tara Master-Hunter, MD
Amy Locke, MD, FAAFP

Department of Family Medicine, University of Michigan, Ann Arbor (Drs. Schneiderhan and Master-Hunter); Department of Family and Preventive Medicine, University of Utah, Salt Lake City (Dr. Locke)

jillsch@umich.edu

The authors reported no potential conflict of interest relevant to this article.

Article PDF
Article PDF
Related Articles

PRACTICE RECOMMENDATIONS

› Encourage patients to eat a healthy diet that includes an adequate amount of soluble fiber to maintain a healthy, diverse microbiome. B
› Recommend combination probiotics to treat symptoms of irritable bowel syndrome. A
› Encourage patients to take probiotics containing Lactobacillus species to prevent antibiotic-associated diarrhea and Saccharomyces to prevent Clostridium difficile infection. A
› Recommend probiotics containing Lactobacillus species and/or Saccharomyces to treat acute infectious diarrhea. A

Strength of recommendation (SOR)

A Good-quality patient-oriented evidence
B Inconsistent or limited-quality patient-oriented evidence
C
Consensus, usual practice, opinion, disease-oriented evidence, case series

CASE 1 Sheila S, age 27, has irritable bowel syndrome (IBS) and comes to your office for a follow-up visit. Over the past 6 months she has started taking a fiber supplement, drinking more water, and looking for links between stress and her symptoms. She has read about probiotics and wonders if you would consider recommending them in her situation.

CASE 2 Mark M, age 45, has type 2 diabetes and is overweight. He is motivated to change his diet and has started to exercise more. He is taking metformin 2000 mg/d but his hemoglobin A1c remains slightly elevated at 7.2%. He heard on television that probiotics might help to keep him from needing to add another medication.

Most of the living organisms that comprise the human microbiome—all of the microbes that live on or in humans—are found in the gastrointestinal (GI) tract. The gut flora contribute 99% of the genetic material in the human body. The composition of the gut flora is remarkably diverse across the population; each individual has a unique microbial footprint. Within this microbial diversity, there appears to be a stable number of genes that are responsible for the major functions of the gut flora.1 These microbes:

  • supply essential nutrients by breaking down complex carbohydrates;
  • generate secondary bile acids that assist in digesting fats;2
  • synthesize vitamins such as K, B12, folate, and biotin;3
  • contribute to the defensive barrier in the colon by keeping pathogenic bacteria from crossing the colonic mucosa; and
  • interact with our systemic immune system in a way that maintains a level of homeostasis, allowing for appropriate activation in the face of pathogens without developing autoimmunity.4

The gut flora also play a role in the communication between the central nervous system and the enteric nervous system by modulating the hormonal and neural pathways that have been labeled the “gut-brain axis.” The gut-brain axis has been associated with numerous disease states, including irritable bowel syndrome and certain psychiatric disorders.5

Researchers are investigating interventions that target the microbiome to increase microbial diversity and the presence of certain species to prevent or treat various diseases. The use of probiotics and dietary changes to increase intake of soluble fiber have been the most studied of these interventions. The thought is that these interventions can correct an imbalance, or dysbiosis, of the gut flora.6 Studies have shown that decreased microbial diversity is associated with elevations of certain disease markers (eg, adiposity, insulin, triglycerides, C–reactive protein)7 and that increases in soluble fiber lead to the greatest long-term improvement in microbial diversity.8 Fecal transplant—the transfer of a processed mixture of stool that contains “healthy” bacteria from a donor into the intestines of a patient—is being explored as a method of replacing colonic gut flora, but evidence is limited.

The following review takes a closer look at these options and identifies those that are most likely to benefit patients in the treatment—and prevention—of several diseases (TABLE 1).9-16

Evidence is best for using probiotics for digestive diseases

Dietary interventions for digestive diseases have long been studied, but are getting renewed attention for their potential impact on the microbiome.17 Beyond dietary modification, other similar treatment options include probiotics (live microorganisms thought to confer a beneficial effect on the host), prebiotics (non-digestible food ingredients, including oligosaccharides and inulin, thought to promote the growth of “helpful” gut flora), and synbiotics (combinations of the 2).18

Irritable bowel syndrome (IBS) is a heterogeneous disorder characterized by altered intestinal transit, low-grade colonic inflammation, and/or alterations in the gutbrain axis. Research has increasingly focused on recently discovered increases in intestinal immune activation, intestinal permeability, and alterations in the colonic microbiome (decreased diversity and increased pathogenic bacteria) associated with IBS.19

Meta-analyses have found that combination probiotics benefit patients with ulcerative colitis, but not those with Crohn’s disease.

A meta-analysis of 43 randomized control trials (RCTs) found probiotics ranging from Lactobacillus to Saccharomyces can significantly decrease global IBS symptoms, abdominal pain, bloating, and flatulence.9 For a patient such as Ms. S, the evidence suggests a probiotic that contains a mixture of Lactobacillus and Bifidobacterium might help relieve her symptoms.9 In terms of dietary modifications, soluble fiber, which is already known to help treat IBS,20 has profound effects on improving microbiota diversity and in shifting the composition toward less pathogenic strains.21 The Institute of Medicine's daily recommended intake of soluble fiber is about 15 g/d.22

Inflammatory bowel disease (IBD) is caused by inflammation of the GI lining due to an overactive immune response. Evidence shows that patients with IBD have an altered microbial composition—specifically, an increase in bacteria that produce pro-inflammatory molecules and a decrease in bacteria that have a dampening effect on immune activation.23

Most studies evaluating probiotics as a treatment for IBD have been small and have used a wide variety of bacterial mixtures, which makes comparisons difficult. Recent meta-analyses found combination probiotics can both induce and maintain remission in patients with ulcerative colitis, but have no beneficial effects in Crohn’s disease.10 In a review of 9 case series of patients with IBD, fecal transplant reduced IBD symptoms, and patients were able to decrease medication use.24

Diarrheal illness. The human intestine is protected from diarrheal illness by healthy bacteria that block the actions of pathogenic bacteria. This mechanism is called colonization resistance. Moderate levels of evidence support the use of probiotics to prevent or treat several types of diarrheal illness.14

Antibiotic-associated diarrhea (AAD) is caused when antibiotic use alters the microbial balance. Recent meta-analyses have shown probiotics can prevent AAD and Clostridium difficile-associated diarrhea.11,12 Several case series and one RCT have found that fecal transplants are safe and efficacious for treating recurrent Clostridium difficile infection.25 Using probiotics to treat symptoms of AAD has been less studied.

Acute infectious diarrhea and traveler’s diarrhea (TD). A Cochrane review found that probiotics decreased the duration of diarrheal episodes by 25 hours, decreased the risk of an episode lasting more than 4 days by 59%, and led to one less diarrheal stool per day by the second day of the intervention.13 In a separate meta-analysis of 12 studies, probiotics significantly prevented 85% of cases of TD.14

Encouraging early evidence for several other illnesses

Metabolic disorders. Both animal and human studies support the theory that gut flora contribute to energy homeostasis, and in some genetically predisposed people dysbiosis may lead to obesity and diabetes. The traditional western diet4 and possibly decreased physical activity26 are major contributors to gut flora dysbiosis. Healthy bacteria in the gut break down soluble fiber into short chain fatty acids (SCFAs). SCFAs are associated with increased satiety, decreased food intake, lower levels of inflammation, and improvement in insulin signaling in adipose tissue. In addition to decreased SFCA production, dysbiosis also leads to increased lipid deposition through higher levels of lipoprotein lipase.27

Obesity. The bacteria in our gut affect energy metabolism. In patients with obesity, increased amounts of bacteria in the taxa Firmicutes and a corresponding decrease in Bacteroidetes is associated with an increased energy harvest and decreased SCFA production, which leads to a pro-inflammatory state.28 Probiotics that contain Bifidobacterium and Lactobacillus are thought to help correct this dysbiosis by increasing production of SCFAs.28

A recent meta-analysis of 4 RCTs found no significant difference between supplementation with probiotics and placebo on weight reduction.29 However, lower-quality studies with more subjects and longer duration have shown a statistically significant improvement in weight reduction with probiotic use compared to placebo.29

The evidence suggests that fecal transplants are safe and efficacious for treating recurrent Clostridium difficile infection.

Diabetes. Although dietary interventions to improve glycemic control have long been an important cornerstone of treatment, probiotic supplementation to further alter gut flora composition is also being evaluated. Studies have found probiotics have largely beneficial effects on glycemic control, especially in animals. The largest systematic review to date looked at 33 studies, including 5 human trials. The human studies each found a significant reduction in at least one of 6 parameters of glycemic control (levels of fasting plasma glucose, postprandial blood glucose, glycated hemoglobin, insulin, insulin resistance, and onset of diabetes).16 It is unclear which probiotic strains confer benefit, and if those benefits are sustainable without dietary modification and increased physical activity.

Psychiatric illnesses. The gut-brain axis is thought to impact mental health by several mechanisms, including modulating the hypothalamic-pituitary-adrenal axis, activating the immune system, producing active metabolites, and affecting the vagus nerve. It is unclear which of these pathways may be clinically relevant.5,30 The few human studies that have looked for a potential link between gut flora and psychiatric illness have focused on depression and autism spectrum disorders (ASD).

Depression. Small studies comparing the microbiome composition of depressed patients vs healthy controls have found differences in patterns of both over- and underrepresented microbiota species in depressed patients, although the patterns across studies have been inconsistent.31,32 One small functional magnetic resonance imaging study of healthy women showed that a fermented milk product that contained probiotics affected activity in areas of the brain that control emotion and sensation.33 A few small studies have shown that patients who used probiotics had improved depression scores.34 Further studies are needed.

ASD. Children with ASD have GI disturbances—most commonly diarrhea, constipation, and/or bloating—more often than healthy controls.35,36 This association has led to speculation of a connection between the gut and brain. The microbial composition and diversity appears to be different in individuals with ASD; several studies have found an increase in Clostridia species.37

Research on probiotics for treating ASD has been primarily in preclinical models. Human studies of probiotics for ASD are lacking.38 Small studies on dietary modifications such as gluten-free and casein-free diets have had varying results; to what extent these dietary changes exert their influence via the intestinal microbiome is unknown.38

Eczema. Several studies have looked at the role of prebiotics and probiotics in reducing the risk for allergic disease. A 2013 Cochrane review found strong evidence that certain prebiotics can prevent eczema in children under age 2.15 There is limited evidence that probiotics may also play a role in preventing eczema.39,40 However, probiotics do not appear to be effective for treating eczema.41

Several studies have found a link between the use of probiotics and significant reductions in at least one of 6 parameters of glycemic control.

Rheumatoid arthritis (RA). Patients with RA have a change in the balance of function of different T helper cells subsets, and several studies have shown that changes in the gut microbiome can affect this balance.42 A recent small study of patients with RA found that 75% of those with new onset RA had Prevotella copri bacteria as the predominant species, and patients with chronic RA had a decrease in Bacteroides species compared to healthy counterparts.42-44 The exact influence of gut flora dysbiosis on RA is unknown.45 Small studies suggest dietary changes may improve RA symptoms, while data on the use of probiotics to alleviate symptoms is mixed.46

 

 

What to tell patients about gut flora and health

There is increasing evidence that the gut microbiome and the genes contained therein have an impact on an individual’s health. (See TABLE 2 for additional resources.) The best preventive advice for patients and their families is to eat a diet rich in fruits and vegetables. This measure has well proven benefits beyond its potential effects on gut flora.

Correcting dysbiosis with diet or probiotics may play a role in treating chronic conditions; however, in many cases, further research is required to elucidate specific recommendations. In the meantime, given the safety profile of probiotics and dietary fiber, it is reasonable to consider using these interventions, particularly probiotics for treating IBS, ulcerative colitis, and acute infectious diarrhea; probiotics for preventing antibiotic-associated diarrhea and traveler’s diarrhea; and prebiotics for preventing eczema in high-risk infants.

CORRESPONDENCE
Jill Schneiderhan, MD, Family Medicine at Domino’s Farms, 24 Frank Lloyd Wright Dr., Lobby H, Suite 2300, Ann Arbor, MI 48105; jillsch@umich.edu.

PRACTICE RECOMMENDATIONS

› Encourage patients to eat a healthy diet that includes an adequate amount of soluble fiber to maintain a healthy, diverse microbiome. B
› Recommend combination probiotics to treat symptoms of irritable bowel syndrome. A
› Encourage patients to take probiotics containing Lactobacillus species to prevent antibiotic-associated diarrhea and Saccharomyces to prevent Clostridium difficile infection. A
› Recommend probiotics containing Lactobacillus species and/or Saccharomyces to treat acute infectious diarrhea. A

Strength of recommendation (SOR)

A Good-quality patient-oriented evidence
B Inconsistent or limited-quality patient-oriented evidence
C
Consensus, usual practice, opinion, disease-oriented evidence, case series

CASE 1 Sheila S, age 27, has irritable bowel syndrome (IBS) and comes to your office for a follow-up visit. Over the past 6 months she has started taking a fiber supplement, drinking more water, and looking for links between stress and her symptoms. She has read about probiotics and wonders if you would consider recommending them in her situation.

CASE 2 Mark M, age 45, has type 2 diabetes and is overweight. He is motivated to change his diet and has started to exercise more. He is taking metformin 2000 mg/d but his hemoglobin A1c remains slightly elevated at 7.2%. He heard on television that probiotics might help to keep him from needing to add another medication.

Most of the living organisms that comprise the human microbiome—all of the microbes that live on or in humans—are found in the gastrointestinal (GI) tract. The gut flora contribute 99% of the genetic material in the human body. The composition of the gut flora is remarkably diverse across the population; each individual has a unique microbial footprint. Within this microbial diversity, there appears to be a stable number of genes that are responsible for the major functions of the gut flora.1 These microbes:

  • supply essential nutrients by breaking down complex carbohydrates;
  • generate secondary bile acids that assist in digesting fats;2
  • synthesize vitamins such as K, B12, folate, and biotin;3
  • contribute to the defensive barrier in the colon by keeping pathogenic bacteria from crossing the colonic mucosa; and
  • interact with our systemic immune system in a way that maintains a level of homeostasis, allowing for appropriate activation in the face of pathogens without developing autoimmunity.4

The gut flora also play a role in the communication between the central nervous system and the enteric nervous system by modulating the hormonal and neural pathways that have been labeled the “gut-brain axis.” The gut-brain axis has been associated with numerous disease states, including irritable bowel syndrome and certain psychiatric disorders.5

Researchers are investigating interventions that target the microbiome to increase microbial diversity and the presence of certain species to prevent or treat various diseases. The use of probiotics and dietary changes to increase intake of soluble fiber have been the most studied of these interventions. The thought is that these interventions can correct an imbalance, or dysbiosis, of the gut flora.6 Studies have shown that decreased microbial diversity is associated with elevations of certain disease markers (eg, adiposity, insulin, triglycerides, C–reactive protein)7 and that increases in soluble fiber lead to the greatest long-term improvement in microbial diversity.8 Fecal transplant—the transfer of a processed mixture of stool that contains “healthy” bacteria from a donor into the intestines of a patient—is being explored as a method of replacing colonic gut flora, but evidence is limited.

The following review takes a closer look at these options and identifies those that are most likely to benefit patients in the treatment—and prevention—of several diseases (TABLE 1).9-16

Evidence is best for using probiotics for digestive diseases

Dietary interventions for digestive diseases have long been studied, but are getting renewed attention for their potential impact on the microbiome.17 Beyond dietary modification, other similar treatment options include probiotics (live microorganisms thought to confer a beneficial effect on the host), prebiotics (non-digestible food ingredients, including oligosaccharides and inulin, thought to promote the growth of “helpful” gut flora), and synbiotics (combinations of the 2).18

Irritable bowel syndrome (IBS) is a heterogeneous disorder characterized by altered intestinal transit, low-grade colonic inflammation, and/or alterations in the gutbrain axis. Research has increasingly focused on recently discovered increases in intestinal immune activation, intestinal permeability, and alterations in the colonic microbiome (decreased diversity and increased pathogenic bacteria) associated with IBS.19

Meta-analyses have found that combination probiotics benefit patients with ulcerative colitis, but not those with Crohn’s disease.

A meta-analysis of 43 randomized control trials (RCTs) found probiotics ranging from Lactobacillus to Saccharomyces can significantly decrease global IBS symptoms, abdominal pain, bloating, and flatulence.9 For a patient such as Ms. S, the evidence suggests a probiotic that contains a mixture of Lactobacillus and Bifidobacterium might help relieve her symptoms.9 In terms of dietary modifications, soluble fiber, which is already known to help treat IBS,20 has profound effects on improving microbiota diversity and in shifting the composition toward less pathogenic strains.21 The Institute of Medicine's daily recommended intake of soluble fiber is about 15 g/d.22

Inflammatory bowel disease (IBD) is caused by inflammation of the GI lining due to an overactive immune response. Evidence shows that patients with IBD have an altered microbial composition—specifically, an increase in bacteria that produce pro-inflammatory molecules and a decrease in bacteria that have a dampening effect on immune activation.23

Most studies evaluating probiotics as a treatment for IBD have been small and have used a wide variety of bacterial mixtures, which makes comparisons difficult. Recent meta-analyses found combination probiotics can both induce and maintain remission in patients with ulcerative colitis, but have no beneficial effects in Crohn’s disease.10 In a review of 9 case series of patients with IBD, fecal transplant reduced IBD symptoms, and patients were able to decrease medication use.24

Diarrheal illness. The human intestine is protected from diarrheal illness by healthy bacteria that block the actions of pathogenic bacteria. This mechanism is called colonization resistance. Moderate levels of evidence support the use of probiotics to prevent or treat several types of diarrheal illness.14

Antibiotic-associated diarrhea (AAD) is caused when antibiotic use alters the microbial balance. Recent meta-analyses have shown probiotics can prevent AAD and Clostridium difficile-associated diarrhea.11,12 Several case series and one RCT have found that fecal transplants are safe and efficacious for treating recurrent Clostridium difficile infection.25 Using probiotics to treat symptoms of AAD has been less studied.

Acute infectious diarrhea and traveler’s diarrhea (TD). A Cochrane review found that probiotics decreased the duration of diarrheal episodes by 25 hours, decreased the risk of an episode lasting more than 4 days by 59%, and led to one less diarrheal stool per day by the second day of the intervention.13 In a separate meta-analysis of 12 studies, probiotics significantly prevented 85% of cases of TD.14

Encouraging early evidence for several other illnesses

Metabolic disorders. Both animal and human studies support the theory that gut flora contribute to energy homeostasis, and in some genetically predisposed people dysbiosis may lead to obesity and diabetes. The traditional western diet4 and possibly decreased physical activity26 are major contributors to gut flora dysbiosis. Healthy bacteria in the gut break down soluble fiber into short chain fatty acids (SCFAs). SCFAs are associated with increased satiety, decreased food intake, lower levels of inflammation, and improvement in insulin signaling in adipose tissue. In addition to decreased SFCA production, dysbiosis also leads to increased lipid deposition through higher levels of lipoprotein lipase.27

Obesity. The bacteria in our gut affect energy metabolism. In patients with obesity, increased amounts of bacteria in the taxa Firmicutes and a corresponding decrease in Bacteroidetes is associated with an increased energy harvest and decreased SCFA production, which leads to a pro-inflammatory state.28 Probiotics that contain Bifidobacterium and Lactobacillus are thought to help correct this dysbiosis by increasing production of SCFAs.28

A recent meta-analysis of 4 RCTs found no significant difference between supplementation with probiotics and placebo on weight reduction.29 However, lower-quality studies with more subjects and longer duration have shown a statistically significant improvement in weight reduction with probiotic use compared to placebo.29

The evidence suggests that fecal transplants are safe and efficacious for treating recurrent Clostridium difficile infection.

Diabetes. Although dietary interventions to improve glycemic control have long been an important cornerstone of treatment, probiotic supplementation to further alter gut flora composition is also being evaluated. Studies have found probiotics have largely beneficial effects on glycemic control, especially in animals. The largest systematic review to date looked at 33 studies, including 5 human trials. The human studies each found a significant reduction in at least one of 6 parameters of glycemic control (levels of fasting plasma glucose, postprandial blood glucose, glycated hemoglobin, insulin, insulin resistance, and onset of diabetes).16 It is unclear which probiotic strains confer benefit, and if those benefits are sustainable without dietary modification and increased physical activity.

Psychiatric illnesses. The gut-brain axis is thought to impact mental health by several mechanisms, including modulating the hypothalamic-pituitary-adrenal axis, activating the immune system, producing active metabolites, and affecting the vagus nerve. It is unclear which of these pathways may be clinically relevant.5,30 The few human studies that have looked for a potential link between gut flora and psychiatric illness have focused on depression and autism spectrum disorders (ASD).

Depression. Small studies comparing the microbiome composition of depressed patients vs healthy controls have found differences in patterns of both over- and underrepresented microbiota species in depressed patients, although the patterns across studies have been inconsistent.31,32 One small functional magnetic resonance imaging study of healthy women showed that a fermented milk product that contained probiotics affected activity in areas of the brain that control emotion and sensation.33 A few small studies have shown that patients who used probiotics had improved depression scores.34 Further studies are needed.

ASD. Children with ASD have GI disturbances—most commonly diarrhea, constipation, and/or bloating—more often than healthy controls.35,36 This association has led to speculation of a connection between the gut and brain. The microbial composition and diversity appears to be different in individuals with ASD; several studies have found an increase in Clostridia species.37

Research on probiotics for treating ASD has been primarily in preclinical models. Human studies of probiotics for ASD are lacking.38 Small studies on dietary modifications such as gluten-free and casein-free diets have had varying results; to what extent these dietary changes exert their influence via the intestinal microbiome is unknown.38

Eczema. Several studies have looked at the role of prebiotics and probiotics in reducing the risk for allergic disease. A 2013 Cochrane review found strong evidence that certain prebiotics can prevent eczema in children under age 2.15 There is limited evidence that probiotics may also play a role in preventing eczema.39,40 However, probiotics do not appear to be effective for treating eczema.41

Several studies have found a link between the use of probiotics and significant reductions in at least one of 6 parameters of glycemic control.

Rheumatoid arthritis (RA). Patients with RA have a change in the balance of function of different T helper cells subsets, and several studies have shown that changes in the gut microbiome can affect this balance.42 A recent small study of patients with RA found that 75% of those with new onset RA had Prevotella copri bacteria as the predominant species, and patients with chronic RA had a decrease in Bacteroides species compared to healthy counterparts.42-44 The exact influence of gut flora dysbiosis on RA is unknown.45 Small studies suggest dietary changes may improve RA symptoms, while data on the use of probiotics to alleviate symptoms is mixed.46

 

 

What to tell patients about gut flora and health

There is increasing evidence that the gut microbiome and the genes contained therein have an impact on an individual’s health. (See TABLE 2 for additional resources.) The best preventive advice for patients and their families is to eat a diet rich in fruits and vegetables. This measure has well proven benefits beyond its potential effects on gut flora.

Correcting dysbiosis with diet or probiotics may play a role in treating chronic conditions; however, in many cases, further research is required to elucidate specific recommendations. In the meantime, given the safety profile of probiotics and dietary fiber, it is reasonable to consider using these interventions, particularly probiotics for treating IBS, ulcerative colitis, and acute infectious diarrhea; probiotics for preventing antibiotic-associated diarrhea and traveler’s diarrhea; and prebiotics for preventing eczema in high-risk infants.

CORRESPONDENCE
Jill Schneiderhan, MD, Family Medicine at Domino’s Farms, 24 Frank Lloyd Wright Dr., Lobby H, Suite 2300, Ann Arbor, MI 48105; jillsch@umich.edu.

References

1. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486(7402):207-214.

2. Conlon MA, Bird AR. The impact of diet and lifestyle on gut microbiota and human health. Nutrients. 2015;7:17-44.

3. Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions. Science. 2012;336:1262-1267.

4. Zhang YJ, Li S, Gan RY, et al. Impacts of gut bacteria on human health and diseases. Int J Mol Sci. 2015;16:7493-7519.

5. Tillisch K. The effects of gut microbiota on CNS function in humans. Gut Microbes. 2014;5:404-410.

6. Belizario JE, Napolitano M. Human microbiomes and their roles in dysbiosis, common diseases, and novel therapeutic approaches. Front Microbiol. 2015;6:1050.

7. Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500:541-546.

8. Cotillard A, Kennedy SP, Kong LC, et al. Dietary intervention impact on gut microbial gene richness. Nature. 2013;500:585-588.

9. Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014;109:1547-1561; quiz 1546,1562.

10. Fujiya M, Ueno N, Kohgo Y. Probiotic treatments for induction and maintenance of remission in inflammatory bowel diseases: a meta-analysis of randomized controlled trials. Clin J Gastroenterol. 2014;7(1):1-13.

11. Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307:1959-1969.

12. Szajewska H, Kolodziej M. Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2015;42:793–801.

13. Allen SJ, Martinez EG, Gregorio GV, et al. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 2010(11):CD003048.

14. McFarland LV. Meta-analysis of probiotics for the prevention of traveler’s diarrhea. Travel Med Infect Dis. 2007;5:97-105.

15. Osborn DA, Sinn JK. Prebiotics in infants for prevention of allergy. The Cochrane Library. 2013. Cochrane Database Syst Rev. 2013;3:CD006474.

16. Razmpoosh E, Javadi M, Ejtahed HS, et al. Probiotics as beneficial agents in the management of diabetes mellitus: a systematic review. Diabetes Metab Res Rev. 2015. [Epub ahead of print].

17. Aguirre M, Eck A, Savelkoul PH, et al. Diet drives quick changes in the metabolic activity and composition of human gut microbiota in a validated in vitro gut model. Res Microbiol. 2015. [Epub ahead of print].

18. Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology. 2009;136:65-80.

19. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015;313:949-958.

20. Moayyedi P, Quigley EM, Lacy BE, et al. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109:1367-1374.

21. Simpson HL, Campbell BJ. Review article: dietary fibre-microbiota interactions. Aliment Pharmacol Ther. 2015;42:158-179.

22. Otten JJ, Hellwig JP, Meyers LD; Institute of Medicine of the National Academies. Dietary Reference Intakes: The essential guide to nutrient requirements. 2006. US Department of Agriculture Web site. Available at: http://www.nal.usda.gov/fnic/DRI/Essential_Guide/DRIEssentialGuideNutReq.pdf. Accessed December 8, 2015.

23. Hansen JJ, Sartor RB. Therapeutic manipulation of the microbiome in IBD: current results and future approaches. Curr Treat Options Gastroenterol. 2015;13:105-120.

24. Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther. 2012;36:503-516.

25. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol. 2014;48:693-702.

26. Bermon S, Petriz B, Kajeniene A, et al. The microbiota: an exercise immunology perspective. Exerc Immunol Rev. 2015;21:70-79.

27. Hur KY, Lee MS. Gut microbiota and metabolic disorders. Diabetes Metab J. 2015;39:198-203.

28. Devaraj S, Hemarajata P, Versalovic J. The human gut microbiome and body metabolism: implications for obesity and diabetes. Clin Chem. 2013;59:617-628.

29. Park S, Bae JH. Probiotics for weight loss: a systematic review and meta-analysis. Nutr Res. 2015;35:566-575.

30. Petra AI, Panagiotidou S, Hatziagelaki E, et al. Gut-microbiotabrain axis and its effect on neuropsychiatric disorders with suspected immune dysregulation. Clin Ther. 2015;37:984-995.

31. Jiang H, Ling Z, Zhang Y, et al. Altered fecal microbiota composition in patients with major depressive disorder. Brain Behav Immun. 2015;48:186-194.

32. Naseribafrouei A, Hestad K, Avershina E, et al. Correlation between the human fecal microbiota and depression. Neurogastroenterol Motil. 2014;26:1155-1162.

33. Tillisch K, Labus J, Kilpatrick L, et al. Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology. 2013;144:1394-1401.

34. Bested AC, Logan AC, Selhub EM. Intestinal microbiota, probiotics and mental health: from Metchnikoff to modern advances: part III - convergence toward clinical trials. Gut Pathog. 2013;5:4.

35. Krajmalnik-Brown R, Lozupone C, Kang DW, et al. Gut bacteria in children with autism spectrum disorders: challenges and promise of studying how a complex community influences a complex disease. Microb Ecol Health Dis. 2015;26:26914.

36. Buie T. Potential etiologic factors of microbiome disruption in autism. Clin Ther. 2015;37:976-983.

37. Cao X, Lin P, Jiang P, et al. Characteristics of the gastrointestinal microbiome in children with autism spectrum disorder: a systematic review. Shanghai Arch Psychiatry. 2013;25:342-353.

38. Frye RE, Slattery J, MacFabe DF, et al. Approaches to studying and manipulating the enteric microbiome to improve autism symptoms. Microb Ecol Health Dis. 2015;26:26878.

39. Osborn DA, Sinn JK. Probiotics in infants for prevention of allergic disease and food hypersensitivity. Cochrane Database Syst Rev. 2007;(4):CD006475.

40. Tang ML, Lahtinen SJ, Boyle RJ. Probiotics and prebiotics: clinical effects in allergic disease. Curr Opin Pediatr. 2010;22:626-634.

41. Boyle RJ, Bath-Hextall FJ, Leonardi-Bee J, et al. Probiotics for treating eczema. Cochrane Database Syst Rev. 2008;(4):CD006135.

42. Rogier R, Koenders MI, Abdollahi-Roodsaz S. Toll-like receptor mediated modulation of T cell response by commensal intestinal microbiota as a trigger for autoimmune arthritis. J Immunol Res. 2015;2015:527696.

43. Perez-Santiago Ja, Gianella Sa, Massanella Ma, et al. Gut Lactobacillales are associated with higher CD4 and less microbial translocation during HIV infection. AIDS. 2013;27:1921-1931.

44. Scher JU, Sczesnak A, Longman RS, et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife. 2013;2:e01202.

45. Scofield RH. Rheumatic diseases and the microbiome. Int J Rheum Dis. 2014;17:489-492.

46. Sandhya P, Danda D, Sharma D, et al. Does the buck stop with the bugs?: an overview of microbial dysbiosis in rheumatoid arthritis. Int J Rheum Dis. 2015. [Epub ahead of print].

References

1. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486(7402):207-214.

2. Conlon MA, Bird AR. The impact of diet and lifestyle on gut microbiota and human health. Nutrients. 2015;7:17-44.

3. Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions. Science. 2012;336:1262-1267.

4. Zhang YJ, Li S, Gan RY, et al. Impacts of gut bacteria on human health and diseases. Int J Mol Sci. 2015;16:7493-7519.

5. Tillisch K. The effects of gut microbiota on CNS function in humans. Gut Microbes. 2014;5:404-410.

6. Belizario JE, Napolitano M. Human microbiomes and their roles in dysbiosis, common diseases, and novel therapeutic approaches. Front Microbiol. 2015;6:1050.

7. Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500:541-546.

8. Cotillard A, Kennedy SP, Kong LC, et al. Dietary intervention impact on gut microbial gene richness. Nature. 2013;500:585-588.

9. Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014;109:1547-1561; quiz 1546,1562.

10. Fujiya M, Ueno N, Kohgo Y. Probiotic treatments for induction and maintenance of remission in inflammatory bowel diseases: a meta-analysis of randomized controlled trials. Clin J Gastroenterol. 2014;7(1):1-13.

11. Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307:1959-1969.

12. Szajewska H, Kolodziej M. Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2015;42:793–801.

13. Allen SJ, Martinez EG, Gregorio GV, et al. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 2010(11):CD003048.

14. McFarland LV. Meta-analysis of probiotics for the prevention of traveler’s diarrhea. Travel Med Infect Dis. 2007;5:97-105.

15. Osborn DA, Sinn JK. Prebiotics in infants for prevention of allergy. The Cochrane Library. 2013. Cochrane Database Syst Rev. 2013;3:CD006474.

16. Razmpoosh E, Javadi M, Ejtahed HS, et al. Probiotics as beneficial agents in the management of diabetes mellitus: a systematic review. Diabetes Metab Res Rev. 2015. [Epub ahead of print].

17. Aguirre M, Eck A, Savelkoul PH, et al. Diet drives quick changes in the metabolic activity and composition of human gut microbiota in a validated in vitro gut model. Res Microbiol. 2015. [Epub ahead of print].

18. Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology. 2009;136:65-80.

19. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015;313:949-958.

20. Moayyedi P, Quigley EM, Lacy BE, et al. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109:1367-1374.

21. Simpson HL, Campbell BJ. Review article: dietary fibre-microbiota interactions. Aliment Pharmacol Ther. 2015;42:158-179.

22. Otten JJ, Hellwig JP, Meyers LD; Institute of Medicine of the National Academies. Dietary Reference Intakes: The essential guide to nutrient requirements. 2006. US Department of Agriculture Web site. Available at: http://www.nal.usda.gov/fnic/DRI/Essential_Guide/DRIEssentialGuideNutReq.pdf. Accessed December 8, 2015.

23. Hansen JJ, Sartor RB. Therapeutic manipulation of the microbiome in IBD: current results and future approaches. Curr Treat Options Gastroenterol. 2015;13:105-120.

24. Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther. 2012;36:503-516.

25. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol. 2014;48:693-702.

26. Bermon S, Petriz B, Kajeniene A, et al. The microbiota: an exercise immunology perspective. Exerc Immunol Rev. 2015;21:70-79.

27. Hur KY, Lee MS. Gut microbiota and metabolic disorders. Diabetes Metab J. 2015;39:198-203.

28. Devaraj S, Hemarajata P, Versalovic J. The human gut microbiome and body metabolism: implications for obesity and diabetes. Clin Chem. 2013;59:617-628.

29. Park S, Bae JH. Probiotics for weight loss: a systematic review and meta-analysis. Nutr Res. 2015;35:566-575.

30. Petra AI, Panagiotidou S, Hatziagelaki E, et al. Gut-microbiotabrain axis and its effect on neuropsychiatric disorders with suspected immune dysregulation. Clin Ther. 2015;37:984-995.

31. Jiang H, Ling Z, Zhang Y, et al. Altered fecal microbiota composition in patients with major depressive disorder. Brain Behav Immun. 2015;48:186-194.

32. Naseribafrouei A, Hestad K, Avershina E, et al. Correlation between the human fecal microbiota and depression. Neurogastroenterol Motil. 2014;26:1155-1162.

33. Tillisch K, Labus J, Kilpatrick L, et al. Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology. 2013;144:1394-1401.

34. Bested AC, Logan AC, Selhub EM. Intestinal microbiota, probiotics and mental health: from Metchnikoff to modern advances: part III - convergence toward clinical trials. Gut Pathog. 2013;5:4.

35. Krajmalnik-Brown R, Lozupone C, Kang DW, et al. Gut bacteria in children with autism spectrum disorders: challenges and promise of studying how a complex community influences a complex disease. Microb Ecol Health Dis. 2015;26:26914.

36. Buie T. Potential etiologic factors of microbiome disruption in autism. Clin Ther. 2015;37:976-983.

37. Cao X, Lin P, Jiang P, et al. Characteristics of the gastrointestinal microbiome in children with autism spectrum disorder: a systematic review. Shanghai Arch Psychiatry. 2013;25:342-353.

38. Frye RE, Slattery J, MacFabe DF, et al. Approaches to studying and manipulating the enteric microbiome to improve autism symptoms. Microb Ecol Health Dis. 2015;26:26878.

39. Osborn DA, Sinn JK. Probiotics in infants for prevention of allergic disease and food hypersensitivity. Cochrane Database Syst Rev. 2007;(4):CD006475.

40. Tang ML, Lahtinen SJ, Boyle RJ. Probiotics and prebiotics: clinical effects in allergic disease. Curr Opin Pediatr. 2010;22:626-634.

41. Boyle RJ, Bath-Hextall FJ, Leonardi-Bee J, et al. Probiotics for treating eczema. Cochrane Database Syst Rev. 2008;(4):CD006135.

42. Rogier R, Koenders MI, Abdollahi-Roodsaz S. Toll-like receptor mediated modulation of T cell response by commensal intestinal microbiota as a trigger for autoimmune arthritis. J Immunol Res. 2015;2015:527696.

43. Perez-Santiago Ja, Gianella Sa, Massanella Ma, et al. Gut Lactobacillales are associated with higher CD4 and less microbial translocation during HIV infection. AIDS. 2013;27:1921-1931.

44. Scher JU, Sczesnak A, Longman RS, et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife. 2013;2:e01202.

45. Scofield RH. Rheumatic diseases and the microbiome. Int J Rheum Dis. 2014;17:489-492.

46. Sandhya P, Danda D, Sharma D, et al. Does the buck stop with the bugs?: an overview of microbial dysbiosis in rheumatoid arthritis. Int J Rheum Dis. 2015. [Epub ahead of print].

Issue
The Journal of Family Practice - 65(1)
Issue
The Journal of Family Practice - 65(1)
Page Number
34-38
Page Number
34-38
Publications
Publications
Topics
Article Type
Display Headline
Targeting gut flora to treat and prevent disease
Display Headline
Targeting gut flora to treat and prevent disease
Legacy Keywords
Jill Schneiderhan, MD, Tara Master-Hunter, MD, Amy Locke, MD, FAAFP, gut flora, probiotics, prebiotics, nutrition, high-fiber diet, Clostridium difficile infection, irritable bowel syndrome, IBS, Saccharomyces, gastrointestinal tract, gastrointestinal, GI
Legacy Keywords
Jill Schneiderhan, MD, Tara Master-Hunter, MD, Amy Locke, MD, FAAFP, gut flora, probiotics, prebiotics, nutrition, high-fiber diet, Clostridium difficile infection, irritable bowel syndrome, IBS, Saccharomyces, gastrointestinal tract, gastrointestinal, GI
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Pediatric Dermatology Consult - January 2016

Article Type
Changed
Display Headline
Pediatric Dermatology Consult - January 2016

By Ellen S. Haddock and Lawrence F. Eichenfield, M.D.

Urticaria multiforme

Although not the most classic presentation, this patient’s migrating rash is most consistent with urticaria (hives). Urticaria is dermal edema which causes transient edematous and usually pruritic wheals.1,2 Each individual lesion lasts less than 24 hours and disappears without leaving a mark. Urticaria is caused by mast cell activation, which leads to release of antihistamines and other substances that increase capillary and venule permeability, allowing fluid to leak into the extravascular space.1 In children, mast cell activation is usually triggered by infections, drugs, or foods.1

Classic urticaria consists of large, pruritic plaques and may be associated with airway edema. However, urticaria also can present with annular and polycyclic lesions, which may be less pruritic and are not associated with airway edema.3 This “multiple redness” is distinct from erythema multiforme (EM), although often urticaria is confused with EM. Lesions of EM are annular and typically have purpuric or dusky centers, with each lesion lasting a minimum of 1 week.4 Annular lesions in urticaria usually do not have central duskiness or blisters. Often the centers of annular urticaria lesions are relatively normal and edges are raised. Some urticaria, especially in younger children as in this case, is sometimes called “urticaria multiforme” because the ecchymotic centers are reminiscent of, but distinct from, classic target lesions of EM. Urticaria multiforme is commonly misdiagnosed as EM, with 29% of patients originally misdiagnosed in one study.3

Urticaria multiforme occurs most commonly in infants and preschool-aged children,5 although it has been diagnosed in patients as old as 18 years.6 Patients often have had an antecedent bacterial or viral illness, recent treatment with antibiotics, or recent vaccination (67%, 44%, and 11% of patients, respectively, in one series).4 In contrast with classic urticaria, urticaria multiforme has not been associated with food allergy.4

In this case, urticaria multiforme was likely caused by a hypersensitivity reaction to amoxicillin. A reaction to nitrofurantoin was less likely because the patient had been taking it continuously for months without any complications.

Differential diagnosis

 

The differential diagnosis for urticaria multiforme includes EM and a serum sickness–like reaction. The main clue that this patient’s rash was a subtype of urticaria rather than EM was its transience, with individual lesions appearing and disappearing in less than a day.4 In contrast, the lesions of EM are fixed, persisting for a week or longer. While urticaria multiforme may have central ecchymosis (termed “hemorrhagic urticaria”) that looks similar to the dusky centers of EM lesions and persists longer than the transient edematous plaques,1 it resolves quickly with appropriate treatment.4 In contrast, the dusky centers of EM, which are caused by epidermal necrosis, take longer to resolve.4 Dermatographism, if present, would support a diagnosis of urticaria rather than EM. Similarly, facial or acral edema, if present, would support a diagnosis of urticaria multiforme; they are uncommon in EM. In contrast, any necrosis, blistering, or erosions in the centers of the annular lesions or on mucosal membranes would suggest EM, as necrosis, blistering, erosions, and mucosal involvement do not occur in urticaria multiforme.4 We stress that in EM, “the center of the lesion is the center of the action,” while in urticaria, wheals often have relatively normal centers.

 

Although both urticaria and EM lesions may be pruritic, any burning sensation is more suggestive of EM.4 Urticaria multiforme is often associated with antibiotics, vaccinations, and upper respiratory infections, while EM is most commonly associated with herpes simplex infection.4,7

Urticaria multiforme also may appear similar to a serum sickness–like reaction, which is another kind of hypersensitivity reaction triggered by the administration of antibiotics. It is most commonly associated with cefaclor, but also is associated with other antibiotics including amoxicillin.8 As with urticaria, hypersensitivity drug eruptions and serum sickness-like reactions may present with purpuric, polycyclic wheals with central clearing. However, as with EM, the lesions of serum sickness–like reactions are fixed, lasting for days to weeks.4 Facial or acral angioedema may occur in both urticaria multiforme and serum sickness–like reactions, but serum sickness–like reactions are not associated with dermatographism.4  Furthermore, serum sickness–like reactions are typically associated with high-grade fever, myalgia, arthralgia, and lymphadenopathy, which are not seen in urticaria multiforme.4,5

Diagnosis of urticaria multiforme usually can be made by history and physical exam, so lab testing and skin biopsy typically are not necessary.5 If performed, lab work may show modest elevation in erythrocyte sedimentation rate and C-reactive protein, but often these acute-phase reactants are within normal limits, and complete blood count and complete metabolic panel are unremarkable.3,5 Although urticaria multiforme often is associated with antecedent viral or bacterial infections, work-up for infectious etiology typically is not fruitful or helpful.4 If lesions are biopsied, the histology of urticaria multiforme is indistinguishable from other types of acute urticaria, showing dermal edema with perivascular lymphocytic infiltrate.9 In contrast, EM shows exocytosis, spongiosis, and epidermal necrosis.9

 

 

Treatment

The first step in managing urticaria multiforme is discontinuing any unnecessary antibiotic that could be triggering the hypersensitivity reaction. Urticaria multiforme typically resolves within 2 weeks without any treatment and responds to treatment with antihistamines within 24-28 hours.5 Treatment with a histamine1 (H1) blocker such as hydroxyzine, cetirizine, or diphenhydramine may be sufficient to resolve the eruption, but combination therapy with both an H1 blocker and an H2 blocker such as ranitidine can be helpful.4 Treatment with systemic corticosteroids usually is not necessary and should be reserved for severely symptomatic or refractory cases.4,9

One of the reasons that it is important to distinguish urticaria multiforme from EM is to avoid overtreatment with systemic steroids,3 which are rarely required for urticaria multiforme but are sometimes useful, although controversial, for EM.1 Additionally, the correct diagnosis is important for providing anticipatory guidance.6 Patients diagnosed with serum sickness–like reactions should be counseled to avoid unnecessary exposure to the culprit antibiotic in the future. Patients with urticaria multiforme who were taking an antibiotic at the onset of the eruption may consider avoiding the potential culprit antibiotic in the future, but it is important to keep in mind that urticaria multiforme is more strongly associated with antecedent infection than with antibiotic use, and so antibiotic avoidance may not be necessary unless justified by formal allergy testing. EM minor is more commonly associated with a herpes simplex virus infection than a drug reaction, so antibiotic use is less concerning, but patients should be counseled that recurrence is common and prophylactic treatment with acyclovir may be advised for recurrent disease.1

References

 

  1. “Neonatal and Infant Dermatology” (Elsevier Health Sciences: New York, 2014, pp. 456-70).
  2. CRIAI. 2006;30(1):003-012.
  3. Pediatr Dermatol. 1997;14(3):231-4.
  4. Pediatrics. 2007;119(5):e1177-83.
  5. Pediatr Dermatol. 2011;28(4):436-8.
  6. The Journal of Allergy and Clinical Immunology in Practice. 2013;1(5):520-1.
  7. Arch Dermatol. 1993;129(1):92-6.
  8. “The Hypersensitivity Syndromes” in Hurwitz Clinical Pediatric Dermatology. 4 ed. Elsevier: New York, 2011, pp. 455-84.
  9. J Clin Aesthet Dermatol. 2013;6(3):34-9.

Ms. Haddock is a medical student at University of California, San Diego School of Medicine and a research associate at Rady Children’s Hospital, San Diego. Dr. Eichenfield is chief of pediatric and adolescent dermatology at Rady Children’s Hospital-San Diego and professor of medicine and pediatrics at UC San Diego School of Medicine. Dr. Eichenfield and Ms. Haddock said they have no relevant financial disclosures. Email pdnews@frontlinemedcom.com.

Publications
Sections

By Ellen S. Haddock and Lawrence F. Eichenfield, M.D.

Urticaria multiforme

Although not the most classic presentation, this patient’s migrating rash is most consistent with urticaria (hives). Urticaria is dermal edema which causes transient edematous and usually pruritic wheals.1,2 Each individual lesion lasts less than 24 hours and disappears without leaving a mark. Urticaria is caused by mast cell activation, which leads to release of antihistamines and other substances that increase capillary and venule permeability, allowing fluid to leak into the extravascular space.1 In children, mast cell activation is usually triggered by infections, drugs, or foods.1

Classic urticaria consists of large, pruritic plaques and may be associated with airway edema. However, urticaria also can present with annular and polycyclic lesions, which may be less pruritic and are not associated with airway edema.3 This “multiple redness” is distinct from erythema multiforme (EM), although often urticaria is confused with EM. Lesions of EM are annular and typically have purpuric or dusky centers, with each lesion lasting a minimum of 1 week.4 Annular lesions in urticaria usually do not have central duskiness or blisters. Often the centers of annular urticaria lesions are relatively normal and edges are raised. Some urticaria, especially in younger children as in this case, is sometimes called “urticaria multiforme” because the ecchymotic centers are reminiscent of, but distinct from, classic target lesions of EM. Urticaria multiforme is commonly misdiagnosed as EM, with 29% of patients originally misdiagnosed in one study.3

Urticaria multiforme occurs most commonly in infants and preschool-aged children,5 although it has been diagnosed in patients as old as 18 years.6 Patients often have had an antecedent bacterial or viral illness, recent treatment with antibiotics, or recent vaccination (67%, 44%, and 11% of patients, respectively, in one series).4 In contrast with classic urticaria, urticaria multiforme has not been associated with food allergy.4

In this case, urticaria multiforme was likely caused by a hypersensitivity reaction to amoxicillin. A reaction to nitrofurantoin was less likely because the patient had been taking it continuously for months without any complications.

Differential diagnosis

 

The differential diagnosis for urticaria multiforme includes EM and a serum sickness–like reaction. The main clue that this patient’s rash was a subtype of urticaria rather than EM was its transience, with individual lesions appearing and disappearing in less than a day.4 In contrast, the lesions of EM are fixed, persisting for a week or longer. While urticaria multiforme may have central ecchymosis (termed “hemorrhagic urticaria”) that looks similar to the dusky centers of EM lesions and persists longer than the transient edematous plaques,1 it resolves quickly with appropriate treatment.4 In contrast, the dusky centers of EM, which are caused by epidermal necrosis, take longer to resolve.4 Dermatographism, if present, would support a diagnosis of urticaria rather than EM. Similarly, facial or acral edema, if present, would support a diagnosis of urticaria multiforme; they are uncommon in EM. In contrast, any necrosis, blistering, or erosions in the centers of the annular lesions or on mucosal membranes would suggest EM, as necrosis, blistering, erosions, and mucosal involvement do not occur in urticaria multiforme.4 We stress that in EM, “the center of the lesion is the center of the action,” while in urticaria, wheals often have relatively normal centers.

 

Although both urticaria and EM lesions may be pruritic, any burning sensation is more suggestive of EM.4 Urticaria multiforme is often associated with antibiotics, vaccinations, and upper respiratory infections, while EM is most commonly associated with herpes simplex infection.4,7

Urticaria multiforme also may appear similar to a serum sickness–like reaction, which is another kind of hypersensitivity reaction triggered by the administration of antibiotics. It is most commonly associated with cefaclor, but also is associated with other antibiotics including amoxicillin.8 As with urticaria, hypersensitivity drug eruptions and serum sickness-like reactions may present with purpuric, polycyclic wheals with central clearing. However, as with EM, the lesions of serum sickness–like reactions are fixed, lasting for days to weeks.4 Facial or acral angioedema may occur in both urticaria multiforme and serum sickness–like reactions, but serum sickness–like reactions are not associated with dermatographism.4  Furthermore, serum sickness–like reactions are typically associated with high-grade fever, myalgia, arthralgia, and lymphadenopathy, which are not seen in urticaria multiforme.4,5

Diagnosis of urticaria multiforme usually can be made by history and physical exam, so lab testing and skin biopsy typically are not necessary.5 If performed, lab work may show modest elevation in erythrocyte sedimentation rate and C-reactive protein, but often these acute-phase reactants are within normal limits, and complete blood count and complete metabolic panel are unremarkable.3,5 Although urticaria multiforme often is associated with antecedent viral or bacterial infections, work-up for infectious etiology typically is not fruitful or helpful.4 If lesions are biopsied, the histology of urticaria multiforme is indistinguishable from other types of acute urticaria, showing dermal edema with perivascular lymphocytic infiltrate.9 In contrast, EM shows exocytosis, spongiosis, and epidermal necrosis.9

 

 

Treatment

The first step in managing urticaria multiforme is discontinuing any unnecessary antibiotic that could be triggering the hypersensitivity reaction. Urticaria multiforme typically resolves within 2 weeks without any treatment and responds to treatment with antihistamines within 24-28 hours.5 Treatment with a histamine1 (H1) blocker such as hydroxyzine, cetirizine, or diphenhydramine may be sufficient to resolve the eruption, but combination therapy with both an H1 blocker and an H2 blocker such as ranitidine can be helpful.4 Treatment with systemic corticosteroids usually is not necessary and should be reserved for severely symptomatic or refractory cases.4,9

One of the reasons that it is important to distinguish urticaria multiforme from EM is to avoid overtreatment with systemic steroids,3 which are rarely required for urticaria multiforme but are sometimes useful, although controversial, for EM.1 Additionally, the correct diagnosis is important for providing anticipatory guidance.6 Patients diagnosed with serum sickness–like reactions should be counseled to avoid unnecessary exposure to the culprit antibiotic in the future. Patients with urticaria multiforme who were taking an antibiotic at the onset of the eruption may consider avoiding the potential culprit antibiotic in the future, but it is important to keep in mind that urticaria multiforme is more strongly associated with antecedent infection than with antibiotic use, and so antibiotic avoidance may not be necessary unless justified by formal allergy testing. EM minor is more commonly associated with a herpes simplex virus infection than a drug reaction, so antibiotic use is less concerning, but patients should be counseled that recurrence is common and prophylactic treatment with acyclovir may be advised for recurrent disease.1

References

 

  1. “Neonatal and Infant Dermatology” (Elsevier Health Sciences: New York, 2014, pp. 456-70).
  2. CRIAI. 2006;30(1):003-012.
  3. Pediatr Dermatol. 1997;14(3):231-4.
  4. Pediatrics. 2007;119(5):e1177-83.
  5. Pediatr Dermatol. 2011;28(4):436-8.
  6. The Journal of Allergy and Clinical Immunology in Practice. 2013;1(5):520-1.
  7. Arch Dermatol. 1993;129(1):92-6.
  8. “The Hypersensitivity Syndromes” in Hurwitz Clinical Pediatric Dermatology. 4 ed. Elsevier: New York, 2011, pp. 455-84.
  9. J Clin Aesthet Dermatol. 2013;6(3):34-9.

Ms. Haddock is a medical student at University of California, San Diego School of Medicine and a research associate at Rady Children’s Hospital, San Diego. Dr. Eichenfield is chief of pediatric and adolescent dermatology at Rady Children’s Hospital-San Diego and professor of medicine and pediatrics at UC San Diego School of Medicine. Dr. Eichenfield and Ms. Haddock said they have no relevant financial disclosures. Email pdnews@frontlinemedcom.com.

By Ellen S. Haddock and Lawrence F. Eichenfield, M.D.

Urticaria multiforme

Although not the most classic presentation, this patient’s migrating rash is most consistent with urticaria (hives). Urticaria is dermal edema which causes transient edematous and usually pruritic wheals.1,2 Each individual lesion lasts less than 24 hours and disappears without leaving a mark. Urticaria is caused by mast cell activation, which leads to release of antihistamines and other substances that increase capillary and venule permeability, allowing fluid to leak into the extravascular space.1 In children, mast cell activation is usually triggered by infections, drugs, or foods.1

Classic urticaria consists of large, pruritic plaques and may be associated with airway edema. However, urticaria also can present with annular and polycyclic lesions, which may be less pruritic and are not associated with airway edema.3 This “multiple redness” is distinct from erythema multiforme (EM), although often urticaria is confused with EM. Lesions of EM are annular and typically have purpuric or dusky centers, with each lesion lasting a minimum of 1 week.4 Annular lesions in urticaria usually do not have central duskiness or blisters. Often the centers of annular urticaria lesions are relatively normal and edges are raised. Some urticaria, especially in younger children as in this case, is sometimes called “urticaria multiforme” because the ecchymotic centers are reminiscent of, but distinct from, classic target lesions of EM. Urticaria multiforme is commonly misdiagnosed as EM, with 29% of patients originally misdiagnosed in one study.3

Urticaria multiforme occurs most commonly in infants and preschool-aged children,5 although it has been diagnosed in patients as old as 18 years.6 Patients often have had an antecedent bacterial or viral illness, recent treatment with antibiotics, or recent vaccination (67%, 44%, and 11% of patients, respectively, in one series).4 In contrast with classic urticaria, urticaria multiforme has not been associated with food allergy.4

In this case, urticaria multiforme was likely caused by a hypersensitivity reaction to amoxicillin. A reaction to nitrofurantoin was less likely because the patient had been taking it continuously for months without any complications.

Differential diagnosis

 

The differential diagnosis for urticaria multiforme includes EM and a serum sickness–like reaction. The main clue that this patient’s rash was a subtype of urticaria rather than EM was its transience, with individual lesions appearing and disappearing in less than a day.4 In contrast, the lesions of EM are fixed, persisting for a week or longer. While urticaria multiforme may have central ecchymosis (termed “hemorrhagic urticaria”) that looks similar to the dusky centers of EM lesions and persists longer than the transient edematous plaques,1 it resolves quickly with appropriate treatment.4 In contrast, the dusky centers of EM, which are caused by epidermal necrosis, take longer to resolve.4 Dermatographism, if present, would support a diagnosis of urticaria rather than EM. Similarly, facial or acral edema, if present, would support a diagnosis of urticaria multiforme; they are uncommon in EM. In contrast, any necrosis, blistering, or erosions in the centers of the annular lesions or on mucosal membranes would suggest EM, as necrosis, blistering, erosions, and mucosal involvement do not occur in urticaria multiforme.4 We stress that in EM, “the center of the lesion is the center of the action,” while in urticaria, wheals often have relatively normal centers.

 

Although both urticaria and EM lesions may be pruritic, any burning sensation is more suggestive of EM.4 Urticaria multiforme is often associated with antibiotics, vaccinations, and upper respiratory infections, while EM is most commonly associated with herpes simplex infection.4,7

Urticaria multiforme also may appear similar to a serum sickness–like reaction, which is another kind of hypersensitivity reaction triggered by the administration of antibiotics. It is most commonly associated with cefaclor, but also is associated with other antibiotics including amoxicillin.8 As with urticaria, hypersensitivity drug eruptions and serum sickness-like reactions may present with purpuric, polycyclic wheals with central clearing. However, as with EM, the lesions of serum sickness–like reactions are fixed, lasting for days to weeks.4 Facial or acral angioedema may occur in both urticaria multiforme and serum sickness–like reactions, but serum sickness–like reactions are not associated with dermatographism.4  Furthermore, serum sickness–like reactions are typically associated with high-grade fever, myalgia, arthralgia, and lymphadenopathy, which are not seen in urticaria multiforme.4,5

Diagnosis of urticaria multiforme usually can be made by history and physical exam, so lab testing and skin biopsy typically are not necessary.5 If performed, lab work may show modest elevation in erythrocyte sedimentation rate and C-reactive protein, but often these acute-phase reactants are within normal limits, and complete blood count and complete metabolic panel are unremarkable.3,5 Although urticaria multiforme often is associated with antecedent viral or bacterial infections, work-up for infectious etiology typically is not fruitful or helpful.4 If lesions are biopsied, the histology of urticaria multiforme is indistinguishable from other types of acute urticaria, showing dermal edema with perivascular lymphocytic infiltrate.9 In contrast, EM shows exocytosis, spongiosis, and epidermal necrosis.9

 

 

Treatment

The first step in managing urticaria multiforme is discontinuing any unnecessary antibiotic that could be triggering the hypersensitivity reaction. Urticaria multiforme typically resolves within 2 weeks without any treatment and responds to treatment with antihistamines within 24-28 hours.5 Treatment with a histamine1 (H1) blocker such as hydroxyzine, cetirizine, or diphenhydramine may be sufficient to resolve the eruption, but combination therapy with both an H1 blocker and an H2 blocker such as ranitidine can be helpful.4 Treatment with systemic corticosteroids usually is not necessary and should be reserved for severely symptomatic or refractory cases.4,9

One of the reasons that it is important to distinguish urticaria multiforme from EM is to avoid overtreatment with systemic steroids,3 which are rarely required for urticaria multiforme but are sometimes useful, although controversial, for EM.1 Additionally, the correct diagnosis is important for providing anticipatory guidance.6 Patients diagnosed with serum sickness–like reactions should be counseled to avoid unnecessary exposure to the culprit antibiotic in the future. Patients with urticaria multiforme who were taking an antibiotic at the onset of the eruption may consider avoiding the potential culprit antibiotic in the future, but it is important to keep in mind that urticaria multiforme is more strongly associated with antecedent infection than with antibiotic use, and so antibiotic avoidance may not be necessary unless justified by formal allergy testing. EM minor is more commonly associated with a herpes simplex virus infection than a drug reaction, so antibiotic use is less concerning, but patients should be counseled that recurrence is common and prophylactic treatment with acyclovir may be advised for recurrent disease.1

References

 

  1. “Neonatal and Infant Dermatology” (Elsevier Health Sciences: New York, 2014, pp. 456-70).
  2. CRIAI. 2006;30(1):003-012.
  3. Pediatr Dermatol. 1997;14(3):231-4.
  4. Pediatrics. 2007;119(5):e1177-83.
  5. Pediatr Dermatol. 2011;28(4):436-8.
  6. The Journal of Allergy and Clinical Immunology in Practice. 2013;1(5):520-1.
  7. Arch Dermatol. 1993;129(1):92-6.
  8. “The Hypersensitivity Syndromes” in Hurwitz Clinical Pediatric Dermatology. 4 ed. Elsevier: New York, 2011, pp. 455-84.
  9. J Clin Aesthet Dermatol. 2013;6(3):34-9.

Ms. Haddock is a medical student at University of California, San Diego School of Medicine and a research associate at Rady Children’s Hospital, San Diego. Dr. Eichenfield is chief of pediatric and adolescent dermatology at Rady Children’s Hospital-San Diego and professor of medicine and pediatrics at UC San Diego School of Medicine. Dr. Eichenfield and Ms. Haddock said they have no relevant financial disclosures. Email pdnews@frontlinemedcom.com.

Publications
Publications
Article Type
Display Headline
Pediatric Dermatology Consult - January 2016
Display Headline
Pediatric Dermatology Consult - January 2016
Sections
Questionnaire Body

 

 

A 15-month-old male presents with a rash that began on his trunk 2 days ago and has spread to his arms, legs, and face. His parents say that the rash seems to migrate, with individual spots seeming to disappear and then reappear in new locations. The patient is playful and seems unbothered by the rash. He has a history of vesicoureteral reflux, for which he takes prophylactic nitrofurantoin daily. He was diagnosed with otitis media 7 days ago, for which he has been taking amoxicillin. On physical exam, the patient is afebrile. He has pink, edematous annular (ring-shaped) and polycyclic (composed of overlapping circles) plaques on his face, chest, abdomen, back, and upper and lower extremities. Some lesions appear vaguely targetoid with central clearing and raised borders. There is no mucosal involvement, joint involvement, or lymphadenopathy.

 

Disallow All Ads

January 2016 Digital Edition

Article Type
Changed
Pharmacologic obesity management, surgery for IED injuries, personalized health plans, and more.
Publications
Topics
Sections
Pharmacologic obesity management, surgery for IED injuries, personalized health plans, and more.
Pharmacologic obesity management, surgery for IED injuries, personalized health plans, and more.
Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Alternative CME

Advances in Hematology and Oncology (August 2013)

Article Type
Changed
Display Headline
Advances in Hematology and Oncology (August 2013)
Publications
Topics
Sections
Publications
Publications
Topics
Article Type
Display Headline
Advances in Hematology and Oncology (August 2013)
Display Headline
Advances in Hematology and Oncology (August 2013)
Sections
Citation Override
Fed Pract. 2013 August;30(suppl 5)
Disallow All Ads